Identification

Name
Cyclophosphamide
Accession Number
DB00531  (APRD00408)
Type
Small Molecule
Groups
Approved, Investigational
Description

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]

Structure
Thumb
Synonyms
  • (+-)-Cyclophosphamide
  • (RS)-Cyclophosphamide
  • 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
  • Anhydrous cyclophosphamide
  • Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
  • Ciclofosfamida
  • Ciclofosfamide
  • Cyclophosphamid
  • Cyclophosphamide
  • Cyclophosphamide anhydrous
  • Cyclophosphamidum
  • Cytophosphane
  • Ledoxina
  • N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
External IDs
B 518 / NSC 26271 / RCRA Waste Number U058
Product Ingredients
IngredientUNIICASInChI Key
Cyclophosphamide monohydrate8N3DW7272P6055-19-2PWOQRKCAHTVFLB-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyclophosphamideInjection, powder, lyophilized, for solution1 g/50mLIntravenous; OralBaxter Laboratories1959-11-16Not applicableUs
CyclophosphamideCapsule25 mg/1OralAvera Mc Kennan Hospital2015-08-18Not applicableUs
CyclophosphamideCapsule50 mg/1OralWest Ward Pharmaceutical2013-09-16Not applicableUs
CyclophosphamideInjection, powder, lyophilized, for solution2 g/100mLIntravenous; OralBaxter Laboratories1959-11-16Not applicableUs
CyclophosphamideCapsule50 mg/1OralAvera Mc Kennan Hospital2015-04-23Not applicableUs
CyclophosphamideInjection, powder, lyophilized, for solution500 mg/25mLIntravenous; OralBaxter Laboratories1959-11-16Not applicableUs
CyclophosphamideCapsule25 mg/1OralWest Ward Pharmaceutical2013-09-16Not applicableUs
Cytoxan Pws for Inj 1000mg/vialPowder, for solution1000 mgIntravenousBristol Myers Squibb1990-12-312008-10-17Canada
Cytoxan Pws for Inj 2000mg/vialPowder, for solution2000 mgIntravenousBristol Myers Squibb1990-12-312008-10-17Canada
Cytoxan Tab 25mgTablet25 mgOralBristol Myers Squibb1977-12-312008-11-21Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyclophosphamideInjection, powder, for solution1 g/50mLIntravenous; OralBaxter Laboratories2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution2 g/100mLIntravenous; OralBaxter Laboratories2008-05-21Not applicableUs
CyclophosphamideTablet25 mg/1OralRoxane Laboratories1999-08-172016-07-11Us
CyclophosphamideTablet25 mg/1OralPhysicians Total Care, Inc.1999-08-17Not applicableUs
CyclophosphamideInjection, powder, for solution1 g/50mLIntravenous; OralBaxter Laboratories2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution2 g/100mLIntravenous; OralBaxter Laboratories2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution2 g/100mLIntravenous; OralBaxter Laboratories2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution2 g/100mLIntravenous; OralSandoz2014-10-31Not applicableUs
CyclophosphamideInjection, powder, for solution2 g/100mLIntravenous; OralBaxter Laboratories2008-05-21Not applicableUs
CyclophosphamideInjection, powder, for solution500 mg/25mLIntravenous; OralBaxter Laboratories2008-05-21Not applicableUs
International/Other Brands
Cytoxan (Bristol-Myers Squibb) / Endoxan (Actavis) / Neosar / Procytox (Baxter) / Revimmune / Sendoxan (Baxter)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Procytox for Injection 2000mg Pws IVCyclophosphamide (2 g) + Sodium Chloride (900 mg)Powder, for solutionIntravenousCarter Horner Corp.1994-12-312001-05-22Canada
Categories
UNII
6UXW23996M
CAS number
50-18-0
Weight
Average: 261.086
Monoisotopic: 260.02481966
Chemical Formula
C7H15Cl2N2O2P
InChI Key
CMSMOCZEIVJLDB-UHFFFAOYSA-N
InChI
InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
IUPAC Name
2-[bis(2-chloroethyl)amino]-1,3,2λ⁵-oxazaphosphinan-2-one
SMILES
ClCCN(CCCl)P1(=O)NCCCO1

Pharmacology

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Structured Indications
Pharmacodynamics

Cyclophosphamide is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.

Mechanism of action

Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

TargetActionsOrganism
ADNA
cross-linking/alkylation
Human
UNuclear receptor subfamily 1 group I member 2Not AvailableHuman
Absorption

After oral administration, peak concentrations occur at one hour.

Volume of distribution

30-50 L

Protein binding

20% of cyclophosphamide is protein bound with no dose dependent changes. Some metabolites are protein bound to an extent greater than 60%.

Metabolism

Metabolism and activation occurs at the liver. 75% of the drug is activated by cytochrome P450 isoforms, CYP2A6, 2B6, 3A4, 3A5, 2C9, 2C18, and 2C19. The CYP2B6 isoform is the enzyme with the highest 4-hydroxylase activity. Cyclophosphamide undergoes activation to eventually form active metabolites, phosphoramide mustard and acrolein. Cyclophosphamide appears to induce its own metabolism which results in an overall increase in clearance, increased formation of 4-hydroxyl metabolites, and shortened t1/2 values following repeated administration.

Route of elimination

Cyclophosphamide is eliminated primarily in the form of metabolites. 10-20% is excreted unchanged in the urine and 4% is excreted in the bile following IV administration.

Half life

3-12 hours

Clearance

Total body clearance = 63 ± 7.6 L/kg.

Toxicity

Adverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Cyclophosphamide Action PathwayDrug action
Cyclophosphamide Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 3A4CYP3A4*1B(G;G) / (A;G)G AllelleEffect Directly StudiedPatients with this genotype have reduced metabolism of cyclophosphamide to its active form and reduced disease free survival time when using cyclophosphamide to treat node-positive breast cancer.Details
Cytochrome P450 2B6CYP2B6*1G(C;C) / (C;T)C AllelleEffect Directly StudiedPatients with this genotype have reduced metabolism of cyclophosphamide to its active form.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Cyclophosphamide.Experimental
10-hydroxycamptothecinCyclophosphamide may increase the cardiotoxic activities of 10-hydroxycamptothecin.Investigational
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideCyclophosphamide may increase the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-chloroethyl-3-sarcosinamide-1-nitrosoureaCyclophosphamide may increase the cardiotoxic activities of 2-chloroethyl-3-sarcosinamide-1-nitrosourea.Investigational
2-MethoxyestradiolCyclophosphamide may increase the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideCyclophosphamide may increase the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,3'-diindolylmethaneCyclophosphamide may increase the cardiotoxic activities of 3,3'-diindolylmethane.Investigational
3,4-DichloroisocoumarinThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Cyclophosphamide.Experimental
3,4-Dihydroxybenzoic AcidCyclophosphamide may increase the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe risk or severity of adverse effects can be increased when 4-(2-Aminoethyl)Benzenesulfonyl Fluoride is combined with Cyclophosphamide.Experimental
6-O-benzylguanineCyclophosphamide may increase the cardiotoxic activities of 6-O-benzylguanine.Investigational
7-HydroxystaurosporineCyclophosphamide may increase the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental, Investigational
8-azaguanineCyclophosphamide may increase the cardiotoxic activities of 8-azaguanine.Experimental
9-aminocamptothecinCyclophosphamide may increase the cardiotoxic activities of 9-aminocamptothecin.Investigational
AbirateroneThe serum concentration of Cyclophosphamide can be increased when it is combined with Abiraterone.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Cyclophosphamide.Experimental
AclarubicinCyclophosphamide may increase the cardiotoxic activities of Aclarubicin.Investigational
Acridine CarboxamideCyclophosphamide may increase the cardiotoxic activities of Acridine Carboxamide.Investigational
ActeosideCyclophosphamide may increase the cardiotoxic activities of Acteoside.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Cyclophosphamide.Approved
AfimoxifeneCyclophosphamide may increase the cardiotoxic activities of Afimoxifene.Investigational
AfliberceptCyclophosphamide may increase the cardiotoxic activities of Aflibercept.Approved
AlatrofloxacinCyclophosphamide may increase the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleCyclophosphamide may increase the cardiotoxic activities of Albendazole.Approved, Vet Approved
AldesleukinCyclophosphamide may increase the cardiotoxic activities of Aldesleukin.Approved
AlectinibCyclophosphamide may increase the cardiotoxic activities of Alectinib.Approved
AlemtuzumabCyclophosphamide may increase the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlitretinoinCyclophosphamide may increase the cardiotoxic activities of Alitretinoin.Approved, Investigational
AllopurinolThe risk or severity of adverse effects can be increased when Allopurinol is combined with Cyclophosphamide.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Cyclophosphamide.Approved
Alpha-1-proteinase inhibitorThe risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Cyclophosphamide.Approved
AltretamineCyclophosphamide may increase the cardiotoxic activities of Altretamine.Approved
AlvocidibCyclophosphamide may increase the cardiotoxic activities of Alvocidib.Experimental, Investigational
AminoglutethimideCyclophosphamide may increase the cardiotoxic activities of Aminoglutethimide.Approved, Investigational
Aminolevulinic acidCyclophosphamide may increase the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Amiodarone.Approved, Investigational
AmonafideCyclophosphamide may increase the cardiotoxic activities of Amonafide.Investigational
AmprenavirThe risk or severity of adverse effects can be increased when Amprenavir is combined with Cyclophosphamide.Approved
AmrubicinCyclophosphamide may increase the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineCyclophosphamide may increase the cardiotoxic activities of Amsacrine.Approved
AnagrelideCyclophosphamide may increase the cardiotoxic activities of Anagrelide.Approved
AnastrozoleCyclophosphamide may increase the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveCyclophosphamide may increase the cardiotoxic activities of Anecortave.Investigational
annamycinCyclophosphamide may increase the cardiotoxic activities of annamycin.Investigational
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Cyclophosphamide.Approved
AP 12009Cyclophosphamide may increase the cardiotoxic activities of AP 12009.Investigational
AP24534Cyclophosphamide may increase the cardiotoxic activities of AP24534.Investigational
ApaziquoneCyclophosphamide may increase the cardiotoxic activities of Apaziquone.Investigational
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Cyclophosphamide.Approved
AprepitantThe serum concentration of Cyclophosphamide can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe risk or severity of adverse effects can be increased when Aprotinin is combined with Cyclophosphamide.Approved, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Cyclophosphamide.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Cyclophosphamide.Approved, Investigational
ArmodafinilThe metabolism of Cyclophosphamide can be decreased when combined with Armodafinil.Approved, Investigational
Arotinoid acidCyclophosphamide may increase the cardiotoxic activities of Arotinoid acid.Experimental
Arsanilic acidCyclophosphamide may increase the cardiotoxic activities of Arsanilic acid.Experimental, Vet Approved
Arsenic trioxideCyclophosphamide may increase the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Cyclophosphamide can be decreased when combined with Artemether.Approved
AsparaginaseCyclophosphamide may increase the cardiotoxic activities of Asparaginase.Approved
AsunaprevirThe risk or severity of adverse effects can be increased when Asunaprevir is combined with Cyclophosphamide.Approved, Investigational
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Cyclophosphamide.Approved, Investigational
AtezolizumabCyclophosphamide may increase the cardiotoxic activities of Atezolizumab.Approved
AtomoxetineThe metabolism of Cyclophosphamide can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Atorvastatin.Approved
AxitinibCyclophosphamide may increase the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineCyclophosphamide may increase the cardiotoxic activities of Azacitidine.Approved, Investigational
AzathioprineAzathioprine may increase the hepatotoxic activities of Cyclophosphamide.Approved
Azelaic AcidCyclophosphamide may increase the cardiotoxic activities of Azelaic Acid.Approved
BatimastatCyclophosphamide may increase the cardiotoxic activities of Batimastat.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cyclophosphamide.Investigational
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with Cyclophosphamide.Approved
BelinostatCyclophosphamide may increase the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanCyclophosphamide may increase the cardiotoxic activities of Belotecan.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Cyclophosphamide.Approved, Investigational
BendamustineCyclophosphamide may increase the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cyclophosphamide.Approved
BenzamidineThe risk or severity of adverse effects can be increased when Benzamidine is combined with Cyclophosphamide.Experimental
BesifloxacinCyclophosphamide may increase the cardiotoxic activities of Besifloxacin.Approved
BetaxololThe metabolism of Cyclophosphamide can be decreased when combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
BexaroteneCyclophosphamide may increase the cardiotoxic activities of Bexarotene.Approved, Investigational
BicalutamideCyclophosphamide may increase the cardiotoxic activities of Bicalutamide.Approved
BinetrakinCyclophosphamide may increase the cardiotoxic activities of Binetrakin.Investigational
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Cyclophosphamide.Approved, Investigational
BizelesinCyclophosphamide may increase the cardiotoxic activities of Bizelesin.Investigational
BleomycinCyclophosphamide may increase the cardiotoxic activities of Bleomycin.Approved
BlinatumomabCyclophosphamide may increase the cardiotoxic activities of Blinatumomab.Approved
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Cyclophosphamide.Approved, Withdrawn
BortezomibCyclophosphamide may increase the cardiotoxic activities of Bortezomib.Approved, Investigational
BosentanThe serum concentration of Cyclophosphamide can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibCyclophosphamide may increase the cardiotoxic activities of Bosutinib.Approved
Brentuximab vedotinCyclophosphamide may increase the cardiotoxic activities of Brentuximab vedotin.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cyclophosphamide.Approved, Investigational
BroxuridineCyclophosphamide may increase the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Cyclophosphamide may increase the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Cyclophosphamide may increase the cardiotoxic activities of BSI-201.Investigational
BupropionThe metabolism of Cyclophosphamide can be decreased when combined with Bupropion.Approved
BuserelinCyclophosphamide may increase the cardiotoxic activities of Buserelin.Approved
BusulfanCyclophosphamide may increase the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineCyclophosphamide may increase the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelCyclophosphamide may increase the cardiotoxic activities of Cabazitaxel.Approved
CabergolineCyclophosphamide may increase the cardiotoxic activities of Cabergoline.Approved
CabozantinibCyclophosphamide may increase the cardiotoxic activities of Cabozantinib.Approved
CalcipotriolCyclophosphamide may increase the cardiotoxic activities of Calcipotriol.Approved
CamostatThe risk or severity of adverse effects can be increased when Camostat is combined with Cyclophosphamide.Experimental
CamptothecinCyclophosphamide may increase the cardiotoxic activities of Camptothecin.Experimental
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Cyclophosphamide.Experimental
CandoxatrilatThe risk or severity of adverse effects can be increased when Candoxatrilat is combined with Cyclophosphamide.Experimental
CanertinibCyclophosphamide may increase the cardiotoxic activities of Canertinib.Investigational
CapecitabineCyclophosphamide may increase the cardiotoxic activities of Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Cyclophosphamide.Approved
CarbamazepineThe metabolism of Cyclophosphamide can be increased when combined with Carbamazepine.Approved, Investigational
CarboplatinCyclophosphamide may increase the cardiotoxic activities of Carboplatin.Approved
CarboquoneCyclophosphamide may increase the cardiotoxic activities of Carboquone.Experimental
CarboxyamidotriazoleCyclophosphamide may increase the cardiotoxic activities of Carboxyamidotriazole.Investigational
CarfilzomibCyclophosphamide may increase the cardiotoxic activities of Carfilzomib.Approved
CarmofurCyclophosphamide may increase the cardiotoxic activities of Carmofur.Withdrawn
CarmustineCyclophosphamide may increase the cardiotoxic activities of Carmustine.Approved
CatumaxomabCyclophosphamide may increase the cardiotoxic activities of Catumaxomab.Approved, Investigational
CediranibCyclophosphamide may increase the cardiotoxic activities of Cediranib.Investigational
CelecoxibThe metabolism of Cyclophosphamide can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Cyclophosphamide can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cyclophosphamide.Withdrawn
CetuximabCyclophosphamide may increase the cardiotoxic activities of Cetuximab.Approved
ChlorambucilCyclophosphamide may increase the cardiotoxic activities of Chlorambucil.Approved
ChloramphenicolThe metabolism of Cyclophosphamide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Cyclophosphamide can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cyclophosphamide.Approved, Vet Approved
ChlorotrianiseneCyclophosphamide may increase the cardiotoxic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorpromazineThe metabolism of Cyclophosphamide can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Cyclophosphamide.Approved
CholecalciferolThe metabolism of Cyclophosphamide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolCyclophosphamide may increase the cardiotoxic activities of Cholesterol.Experimental, Investigational
ChymostatinThe risk or severity of adverse effects can be increased when Chymostatin is combined with Cyclophosphamide.Experimental
CilastatinThe risk or severity of adverse effects can be increased when Cilastatin is combined with Cyclophosphamide.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Cyclophosphamide.Approved
CimetidineThe metabolism of Cyclophosphamide can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Cyclophosphamide can be decreased when combined with Cinacalcet.Approved
CinoxacinCyclophosphamide may increase the cardiotoxic activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinCyclophosphamide may increase the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
CisplatinCyclophosphamide may increase the cardiotoxic activities of Cisplatin.Approved
CitalopramThe metabolism of Cyclophosphamide can be decreased when combined with Citalopram.Approved
CladribineCyclophosphamide may increase the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Cyclophosphamide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Cyclophosphamide can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Cyclophosphamide can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineCyclophosphamide may increase the cardiotoxic activities of Clofarabine.Approved, Investigational
ClomipramineThe metabolism of Cyclophosphamide can be decreased when combined with Clomipramine.Approved, Vet Approved
ClopidogrelThe metabolism of Cyclophosphamide can be decreased when combined with Clopidogrel.Approved, Nutraceutical
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclophosphamide.Approved
ClotrimazoleThe metabolism of Cyclophosphamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Clozapine.Approved
CobicistatThe serum concentration of Cyclophosphamide can be increased when it is combined with Cobicistat.Approved
CobimetinibCyclophosphamide may increase the cardiotoxic activities of Cobimetinib.Approved
CocaineThe metabolism of Cyclophosphamide can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cyclophosphamide.Approved
CombretastatinCyclophosphamide may increase the cardiotoxic activities of Combretastatin.Investigational
ConivaptanThe serum concentration of Cyclophosphamide can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinCyclophosphamide may increase the cardiotoxic activities of Cordycepin.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclophosphamide.Approved
Coumermycin A1Cyclophosphamide may increase the cardiotoxic activities of Coumermycin A1.Experimental
CrenolanibCyclophosphamide may increase the cardiotoxic activities of Crenolanib.Investigational
CrisaboroleThe metabolism of Cyclophosphamide can be decreased when combined with Crisaborole.Approved
CrizotinibCyclophosphamide may increase the cardiotoxic activities of Crizotinib.Approved
CurcuminCyclophosphamide may increase the cardiotoxic activities of Curcumin.Investigational
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Cyclophosphamide.Experimental
CyclosporineCyclophosphamide may increase the immunosuppressive activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Cyclophosphamide.Experimental
Cyproterone acetateCyclophosphamide may increase the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineCyclophosphamide may increase the cardiotoxic activities of Cytarabine.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cyclophosphamide.Approved
DabrafenibThe serum concentration of Cyclophosphamide can be decreased when it is combined with Dabrafenib.Approved
DacarbazineCyclophosphamide may increase the cardiotoxic activities of Dacarbazine.Approved, Investigational
DactinomycinCyclophosphamide may increase the cardiotoxic activities of Dactinomycin.Approved
DaratumumabCyclophosphamide may increase the cardiotoxic activities of Daratumumab.Approved
DarexabanThe risk or severity of adverse effects can be increased when Darexaban is combined with Cyclophosphamide.Investigational
DarifenacinThe metabolism of Cyclophosphamide can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Cyclophosphamide.Approved
DasatinibCyclophosphamide may increase the cardiotoxic activities of Dasatinib.Approved, Investigational
DaunorubicinCyclophosphamide may increase the cardiotoxic activities of Daunorubicin.Approved
DecitabineCyclophosphamide may increase the cardiotoxic activities of Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Cyclophosphamide can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixCyclophosphamide may increase the cardiotoxic activities of Degarelix.Approved
DelanzomibThe risk or severity of adverse effects can be increased when Delanzomib is combined with Cyclophosphamide.Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Cyclophosphamide.Experimental
DelavirdineThe metabolism of Cyclophosphamide can be decreased when combined with Delavirdine.Approved
DemecolcineCyclophosphamide may increase the cardiotoxic activities of Demecolcine.Experimental
Denileukin diftitoxCyclophosphamide may increase the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cyclophosphamide.Approved
DeoxyspergualinCyclophosphamide may increase the cardiotoxic activities of Deoxyspergualin.Investigational
DesipramineThe metabolism of Cyclophosphamide can be decreased when combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cyclophosphamide.Approved
DexamethasoneCyclophosphamide may increase the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneCyclophosphamide may increase the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DianhydrogalactitolCyclophosphamide may increase the cardiotoxic activities of Dianhydrogalactitol.Investigational
DidoxCyclophosphamide may increase the cardiotoxic activities of Didox.Investigational
DienogestCyclophosphamide may increase the cardiotoxic activities of Dienogest.Approved
diethylnorspermineCyclophosphamide may increase the cardiotoxic activities of diethylnorspermine.Investigational
DiethylstilbestrolCyclophosphamide may increase the cardiotoxic activities of Diethylstilbestrol.Approved, Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Cyclophosphamide.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cyclophosphamide.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cyclophosphamide.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cyclophosphamide.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Cyclophosphamide.Experimental
DihydroergotamineThe metabolism of Cyclophosphamide can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Cyclophosphamide can be decreased when combined with Diltiazem.Approved
DinutuximabCyclophosphamide may increase the cardiotoxic activities of Dinutuximab.Approved
DiphenhydramineThe metabolism of Cyclophosphamide can be decreased when combined with Diphenhydramine.Approved
DocetaxelCyclophosphamide may increase the cardiotoxic activities of Docetaxel.Approved, Investigational
Dolastatin 10Cyclophosphamide may increase the cardiotoxic activities of Dolastatin 10.Investigational
DosulepinThe metabolism of Cyclophosphamide can be decreased when combined with Dosulepin.Approved
DoxifluridineCyclophosphamide may increase the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
DoxorubicinCyclophosphamide may increase the cardiotoxic activities of Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Cyclophosphamide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Cyclophosphamide can be decreased when combined with Dronedarone.Approved
DuligotuzumabCyclophosphamide may increase the cardiotoxic activities of Duligotuzumab.Investigational
DuloxetineThe metabolism of Cyclophosphamide can be decreased when combined with Duloxetine.Approved
EcabetCyclophosphamide may increase the cardiotoxic activities of Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cyclophosphamide.Approved
EdrecolomabCyclophosphamide may increase the cardiotoxic activities of Edrecolomab.Experimental, Investigational
EfaproxiralCyclophosphamide may increase the cardiotoxic activities of Efaproxiral.Investigational
EfatutazoneCyclophosphamide may increase the cardiotoxic activities of Efatutazone.Investigational
EfavirenzThe metabolism of Cyclophosphamide can be decreased when combined with Efavirenz.Approved, Investigational
EflornithineCyclophosphamide may increase the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Cyclophosphamide may increase the cardiotoxic activities of EG009.Investigational
ElafinThe risk or severity of adverse effects can be increased when Elafin is combined with Cyclophosphamide.Investigational
EliglustatThe metabolism of Cyclophosphamide can be decreased when combined with Eliglustat.Approved
ElotuzumabCyclophosphamide may increase the cardiotoxic activities of Elotuzumab.Approved
ElsamitrucinCyclophosphamide may increase the cardiotoxic activities of Elsamitrucin.Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Cyclophosphamide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Cyclophosphamide.Approved
EnalkirenThe risk or severity of adverse effects can be increased when Enalkiren is combined with Cyclophosphamide.Experimental
EndostatinCyclophosphamide may increase the cardiotoxic activities of Endostatin.Investigational
EnoxacinCyclophosphamide may increase the cardiotoxic activities of Enoxacin.Approved, Investigational
EnrofloxacinCyclophosphamide may increase the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatCyclophosphamide may increase the cardiotoxic activities of Entinostat.Investigational
EnzalutamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Enzalutamide.Approved
Epigallocatechin GallateCyclophosphamide may increase the cardiotoxic activities of Epigallocatechin Gallate.Investigational
EpirubicinCyclophosphamide may increase the cardiotoxic activities of Epirubicin.Approved
EpofolateCyclophosphamide may increase the cardiotoxic activities of Epofolate.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cyclophosphamide.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Cyclophosphamide.Approved
EribulinCyclophosphamide may increase the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibCyclophosphamide may increase the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Cyclophosphamide can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe metabolism of Cyclophosphamide can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Esomeprazole.Approved, Investigational
EstramustineCyclophosphamide may increase the cardiotoxic activities of Estramustine.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide.Approved, Investigational
EtanidazoleCyclophosphamide may increase the cardiotoxic activities of Etanidazole.Investigational
Ethiodized oilCyclophosphamide may increase the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateCyclophosphamide may increase the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtoglucidCyclophosphamide may increase the cardiotoxic activities of Etoglucid.Experimental
EtoposideCyclophosphamide may increase the cardiotoxic activities of Etoposide.Approved
EtravirineThe metabolism of Cyclophosphamide can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cyclophosphamide.Approved
ExatecanCyclophosphamide may increase the cardiotoxic activities of Exatecan.Investigational
ExemestaneCyclophosphamide may increase the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindCyclophosphamide may increase the cardiotoxic activities of exisulind.Investigational
FaldaprevirThe risk or severity of adverse effects can be increased when Faldaprevir is combined with Cyclophosphamide.Investigational
FelodipineThe metabolism of Cyclophosphamide can be decreased when combined with Felodipine.Approved, Investigational
FenretinideCyclophosphamide may increase the cardiotoxic activities of Fenretinide.Investigational
FiacitabineCyclophosphamide may increase the cardiotoxic activities of Fiacitabine.Investigational
FilgrastimThe risk or severity of adverse effects can be increased when Filgrastim is combined with Cyclophosphamide.Approved
FingolimodCyclophosphamide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinCyclophosphamide may increase the cardiotoxic activities of Fleroxacin.Approved
FloxuridineCyclophosphamide may increase the cardiotoxic activities of Floxuridine.Approved
FluconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Fluconazole.Approved
FludarabineCyclophosphamide may increase the cardiotoxic activities of Fludarabine.Approved
FlumequineCyclophosphamide may increase the cardiotoxic activities of Flumequine.Withdrawn
FluorouracilCyclophosphamide may increase the cardiotoxic activities of Fluorouracil.Approved
FluoxetineThe metabolism of Cyclophosphamide can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlutamideCyclophosphamide may increase the cardiotoxic activities of Flutamide.Approved
FluvastatinThe metabolism of Cyclophosphamide can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Cyclophosphamide can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneCyclophosphamide may increase the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinCyclophosphamide may increase the cardiotoxic activities of Formycin.Experimental
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Cyclophosphamide.Approved
FosaprepitantThe serum concentration of Cyclophosphamide can be increased when it is combined with Fosaprepitant.Approved
FosbretabulinCyclophosphamide may increase the cardiotoxic activities of Fosbretabulin.Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Cyclophosphamide.Approved
FosphenytoinThe metabolism of Cyclophosphamide can be increased when combined with Fosphenytoin.Approved
FotemustineCyclophosphamide may increase the cardiotoxic activities of Fotemustine.Experimental, Investigational
FulvestrantCyclophosphamide may increase the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinCyclophosphamide may increase the cardiotoxic activities of Fumagillin.Experimental
Fusidic AcidThe serum concentration of Cyclophosphamide can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Cyclophosphamide.Investigational
GabexateThe risk or severity of adverse effects can be increased when Gabexate is combined with Cyclophosphamide.Investigational
Gallium nitrateCyclophosphamide may increase the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinCyclophosphamide may increase the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinCyclophosphamide may increase the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibCyclophosphamide may increase the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinCyclophosphamide may increase the cardiotoxic activities of Geldanamycin.Experimental, Investigational
GemcitabineCyclophosphamide may increase the cardiotoxic activities of Gemcitabine.Approved
GemfibrozilThe metabolism of Cyclophosphamide can be decreased when combined with Gemfibrozil.Approved
GemifloxacinCyclophosphamide may increase the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinCyclophosphamide may increase the cardiotoxic activities of Gemtuzumab ozogamicin.Approved
GenisteinCyclophosphamide may increase the cardiotoxic activities of Genistein.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cyclophosphamide.Investigational
Ginsenoside CCyclophosphamide may increase the cardiotoxic activities of Ginsenoside C.Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Cyclophosphamide.Experimental
GM6001The risk or severity of adverse effects can be increased when GM6001 is combined with Cyclophosphamide.Experimental
GoserelinCyclophosphamide may increase the cardiotoxic activities of Goserelin.Approved
GrepafloxacinCyclophosphamide may increase the cardiotoxic activities of Grepafloxacin.Investigational, Withdrawn
GS 0573Cyclophosphamide may increase the cardiotoxic activities of GS 0573.Investigational
GusperimusCyclophosphamide may increase the cardiotoxic activities of Gusperimus.Investigational
HadacidinCyclophosphamide may increase the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneCyclophosphamide may increase the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HaloperidolThe metabolism of Cyclophosphamide can be decreased when combined with Haloperidol.Approved
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclophosphamide.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cyclophosphamide.Approved, Withdrawn
HexestrolCyclophosphamide may increase the cardiotoxic activities of Hexestrol.Withdrawn
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cyclophosphamide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Cyclophosphamide.Approved, Investigational
Hydroxyprogesterone caproateCyclophosphamide may increase the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaCyclophosphamide may increase the cardiotoxic activities of Hydroxyurea.Approved
HypericinCyclophosphamide may increase the cardiotoxic activities of Hypericin.Investigational
IbrutinibCyclophosphamide may increase the cardiotoxic activities of Ibrutinib.Approved
IdarubicinCyclophosphamide may increase the cardiotoxic activities of Idarubicin.Approved
IdelalisibCyclophosphamide may increase the cardiotoxic activities of Idelalisib.Approved
IdraparinuxThe risk or severity of adverse effects can be increased when Idraparinux is combined with Cyclophosphamide.Investigational
IfosfamideCyclophosphamide may increase the cardiotoxic activities of Ifosfamide.Approved
ImatinibCyclophosphamide may increase the cardiotoxic activities of Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Cyclophosphamide.Investigational
ImipramineThe metabolism of Cyclophosphamide can be decreased when combined with Imipramine.Approved
ImiquimodCyclophosphamide may increase the cardiotoxic activities of Imiquimod.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Cyclophosphamide.Approved
IndinavirThe risk or severity of adverse effects can be increased when Indinavir is combined with Cyclophosphamide.Approved
IndirubinCyclophosphamide may increase the cardiotoxic activities of Indirubin.Investigational
Indole-3-carbinolCyclophosphamide may increase the cardiotoxic activities of Indole-3-carbinol.Investigational
InfigratinibCyclophosphamide may increase the cardiotoxic activities of Infigratinib.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Cyclophosphamide.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cyclophosphamide.Investigational
IniparibCyclophosphamide may increase the cardiotoxic activities of Iniparib.Experimental, Investigational
Interferon Alfa-2b, RecombinantCyclophosphamide may increase the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved
Interferon beta-1aCyclophosphamide may increase the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
IobenguaneCyclophosphamide may increase the cardiotoxic activities of Iobenguane.Approved, Investigational
IpilimumabCyclophosphamide may increase the cardiotoxic activities of Ipilimumab.Approved
IrbesartanThe metabolism of Cyclophosphamide can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanCyclophosphamide may increase the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenCyclophosphamide may increase the cardiotoxic activities of Irofulven.Investigational
IrsogladineCyclophosphamide may increase the cardiotoxic activities of Irsogladine.Investigational
IsavuconazoniumThe metabolism of Cyclophosphamide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Cyclophosphamide.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Cyclophosphamide can be decreased when combined with Isoniazid.Approved
IsosorbideCyclophosphamide may increase the cardiotoxic activities of Isosorbide.Approved, Investigational
IsradipineThe metabolism of Cyclophosphamide can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cyclophosphamide can be increased when it is combined with Ivacaftor.Approved
IxabepiloneCyclophosphamide may increase the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibCyclophosphamide may increase the cardiotoxic activities of Ixazomib.Approved
KetoconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Ketoconazole.Approved, Investigational
KOS-1584Cyclophosphamide may increase the cardiotoxic activities of KOS-1584.Investigational
KRN-7000Cyclophosphamide may increase the cardiotoxic activities of KRN-7000.Investigational
L-alanosineCyclophosphamide may increase the cardiotoxic activities of L-alanosine.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Cyclophosphamide.Experimental
LanreotideCyclophosphamide may increase the cardiotoxic activities of Lanreotide.Approved
LapatinibCyclophosphamide may increase the cardiotoxic activities of Lapatinib.Approved, Investigational
LCL-161Cyclophosphamide may increase the cardiotoxic activities of LCL-161.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cyclophosphamide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Leflunomide.Approved, Investigational
LenalidomideCyclophosphamide may increase the cardiotoxic activities of Lenalidomide.Approved
LentinanCyclophosphamide may increase the cardiotoxic activities of Lentinan.Experimental, Investigational
LenvatinibCyclophosphamide may increase the cardiotoxic activities of Lenvatinib.Approved
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Cyclophosphamide.Approved
LetaxabanThe risk or severity of adverse effects can be increased when Letaxaban is combined with Cyclophosphamide.Investigational
LetrozoleCyclophosphamide may increase the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideCyclophosphamide may increase the cardiotoxic activities of Leuprolide.Approved, Investigational
LevofloxacinCyclophosphamide may increase the cardiotoxic activities of Levofloxacin.Approved, Investigational
LiarozoleCyclophosphamide may increase the cardiotoxic activities of Liarozole.Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Cyclophosphamide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Cyclophosphamide.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Cyclophosphamide.Approved, Investigational
LobeglitazoneThe metabolism of Cyclophosphamide can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinCyclophosphamide may increase the cardiotoxic activities of Lomefloxacin.Approved, Investigational
LometrexolCyclophosphamide may increase the cardiotoxic activities of Lometrexol.Investigational
LomustineCyclophosphamide may increase the cardiotoxic activities of Lomustine.Approved
LonidamineCyclophosphamide may increase the cardiotoxic activities of Lonidamine.Approved, Investigational
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Cyclophosphamide.Approved
LorcaserinThe metabolism of Cyclophosphamide can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Cyclophosphamide can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Cyclophosphamide can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Cyclophosphamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Cyclophosphamide can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Cyclophosphamide can be decreased when combined with Lumefantrine.Approved
LurtotecanCyclophosphamide may increase the cardiotoxic activities of Lurtotecan.Investigational
LycopeneCyclophosphamide may increase the cardiotoxic activities of Lycopene.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Cyclophosphamide.Illicit, Investigational, Withdrawn
MafosfamideCyclophosphamide may increase the cardiotoxic activities of Mafosfamide.Investigational
ManidipineThe metabolism of Cyclophosphamide can be decreased when combined with Manidipine.Approved, Investigational
MannosulfanCyclophosphamide may increase the cardiotoxic activities of Mannosulfan.Experimental
MasitinibCyclophosphamide may increase the cardiotoxic activities of Masitinib.Investigational, Vet Approved
MasoprocolCyclophosphamide may increase the cardiotoxic activities of Masoprocol.Approved, Investigational
MaxacalcitolCyclophosphamide may increase the cardiotoxic activities of Maxacalcitol.Approved, Investigational
MebendazoleCyclophosphamide may increase the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineCyclophosphamide may increase the cardiotoxic activities of Mechlorethamine.Approved
MedrogestoneCyclophosphamide may increase the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateCyclophosphamide may increase the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateCyclophosphamide may increase the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MelagatranThe risk or severity of adverse effects can be increased when Melagatran is combined with Cyclophosphamide.Experimental
MelphalanCyclophosphamide may increase the cardiotoxic activities of Melphalan.Approved
MequinolCyclophosphamide may increase the cardiotoxic activities of Mequinol.Approved
MercaptopurineCyclophosphamide may increase the cardiotoxic activities of Mercaptopurine.Approved
MerestinibCyclophosphamide may increase the cardiotoxic activities of Merestinib.Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Cyclophosphamide.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Cyclophosphamide.Experimental
MethadoneThe metabolism of Cyclophosphamide can be decreased when combined with Methadone.Approved
MethotrexateCyclophosphamide may increase the cardiotoxic activities of Methotrexate.Approved
MethotrimeprazineThe metabolism of Cyclophosphamide can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cyclophosphamide.Approved
Methyl aminolevulinateCyclophosphamide may increase the cardiotoxic activities of Methyl aminolevulinate.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Cyclophosphamide.Approved
MethylprednisoloneCyclophosphamide may increase the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethylselenocysteineCyclophosphamide may increase the cardiotoxic activities of Methylselenocysteine.Investigational
MethyltestosteroneCyclophosphamide may increase the cardiotoxic activities of Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Cyclophosphamide.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Cyclophosphamide.Experimental
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Cyclophosphamide.Approved
MetoprineCyclophosphamide may increase the cardiotoxic activities of Metoprine.Experimental
MetoprololThe metabolism of Cyclophosphamide can be decreased when combined with Metoprolol.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Cyclophosphamide.Experimental
MidostaurinCyclophosphamide may increase the cardiotoxic activities of Midostaurin.Approved
MifepristoneThe serum concentration of Cyclophosphamide can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineCyclophosphamide may increase the cardiotoxic activities of Miltefosine.Approved
MirabegronThe metabolism of Cyclophosphamide can be decreased when combined with Mirabegron.Approved
MisonidazoleCyclophosphamide may increase the cardiotoxic activities of Misonidazole.Investigational
MitobronitolCyclophosphamide may increase the cardiotoxic activities of Mitobronitol.Experimental
MitoguazoneCyclophosphamide may increase the cardiotoxic activities of Mitoguazone.Investigational
MitolactolCyclophosphamide may increase the cardiotoxic activities of Mitolactol.Investigational
MitomycinCyclophosphamide may increase the cardiotoxic activities of Mitomycin.Approved
MitotaneThe serum concentration of Cyclophosphamide can be decreased when it is combined with Mitotane.Approved
MitoxantroneCyclophosphamide may increase the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MizoribineCyclophosphamide may increase the cardiotoxic activities of Mizoribine.Investigational
MLN576Cyclophosphamide may increase the cardiotoxic activities of MLN576.Investigational
MoclobemideThe metabolism of Cyclophosphamide can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Cyclophosphamide can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Cyclophosphamide.Approved
MolgramostimCyclophosphamide may increase the cardiotoxic activities of Molgramostim.Investigational
motexafin gadoliniumCyclophosphamide may increase the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinCyclophosphamide may increase the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilCyclophosphamide may increase the cardiotoxic activities of Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidCyclophosphamide may increase the cardiotoxic activities of Mycophenolic acid.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe risk or severity of adverse effects can be increased when N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline is combined with Cyclophosphamide.Experimental
NadifloxacinCyclophosphamide may increase the cardiotoxic activities of Nadifloxacin.Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cyclophosphamide.Approved, Investigational
Nalidixic AcidCyclophosphamide may increase the cardiotoxic activities of Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cyclophosphamide.Approved
NamitecanCyclophosphamide may increase the cardiotoxic activities of Namitecan.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.Approved, Investigational
NavitoclaxCyclophosphamide may increase the cardiotoxic activities of Navitoclax.Investigational
NebularineCyclophosphamide may increase the cardiotoxic activities of Nebularine.Experimental
NecitumumabCyclophosphamide may increase the cardiotoxic activities of Necitumumab.Approved
NedaplatinCyclophosphamide may increase the cardiotoxic activities of Nedaplatin.Approved, Investigational
NefazodoneThe metabolism of Cyclophosphamide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineCyclophosphamide may increase the cardiotoxic activities of Nelarabine.Approved, Investigational
NelfinavirThe risk or severity of adverse effects can be increased when Nelfinavir is combined with Cyclophosphamide.Approved
NetupitantThe serum concentration of Cyclophosphamide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cyclophosphamide can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Cyclophosphamide can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Cyclophosphamide.Approved, Investigational
NicotineThe metabolism of Cyclophosphamide can be decreased when combined with Nicotine.Approved
NiguldipineCyclophosphamide may increase the cardiotoxic activities of Niguldipine.Experimental
NilotinibCyclophosphamide may increase the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideCyclophosphamide may increase the cardiotoxic activities of Nilutamide.Approved
NimustineCyclophosphamide may increase the cardiotoxic activities of Nimustine.Investigational
NintedanibCyclophosphamide may increase the cardiotoxic activities of Nintedanib.Approved
NiraparibCyclophosphamide may increase the cardiotoxic activities of Niraparib.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Cyclophosphamide.Investigational
NivolumabCyclophosphamide may increase the cardiotoxic activities of Nivolumab.Approved
nocodazoleCyclophosphamide may increase the cardiotoxic activities of nocodazole.Experimental
NolatrexedCyclophosphamide may increase the cardiotoxic activities of Nolatrexed.Investigational
NorfloxacinCyclophosphamide may increase the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabCyclophosphamide may increase the cardiotoxic activities of Obinutuzumab.Approved
OblimersenCyclophosphamide may increase the cardiotoxic activities of Oblimersen.Experimental, Investigational
OBP-801Cyclophosphamide may increase the cardiotoxic activities of OBP-801.Investigational
OctreotideCyclophosphamide may increase the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabCyclophosphamide may increase the cardiotoxic activities of Ofatumumab.Approved
OfloxacinCyclophosphamide may increase the cardiotoxic activities of Ofloxacin.Approved
OglufanideCyclophosphamide may increase the cardiotoxic activities of Oglufanide.Investigational
OlaparibCyclophosphamide may increase the cardiotoxic activities of Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Cyclophosphamide.Experimental, Investigational
OltiprazCyclophosphamide may increase the cardiotoxic activities of Oltipraz.Investigational
Omacetaxine mepesuccinateCyclophosphamide may increase the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Cyclophosphamide.Investigational
OmeprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OnapristoneCyclophosphamide may increase the cardiotoxic activities of Onapristone.Investigational
OprelvekinCyclophosphamide may increase the cardiotoxic activities of Oprelvekin.Approved, Investigational
OsimertinibCyclophosphamide may increase the cardiotoxic activities of Osimertinib.Approved
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Cyclophosphamide.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Cyclophosphamide.Approved
OxaliplatinCyclophosphamide may increase the cardiotoxic activities of Oxaliplatin.Approved, Investigational
Oxolinic acidCyclophosphamide may increase the cardiotoxic activities of Oxolinic acid.Experimental
PaclitaxelCyclophosphamide may increase the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
Paclitaxel poliglumexCyclophosphamide may increase the cardiotoxic activities of Paclitaxel poliglumex.Experimental, Investigational
PalbociclibThe serum concentration of Cyclophosphamide can be increased when it is combined with Palbociclib.Approved
PalifosfamideCyclophosphamide may increase the cardiotoxic activities of Palifosfamide.Investigational
PamidronateCyclophosphamide may increase the cardiotoxic activities of Pamidronate.Approved
PanitumumabCyclophosphamide may increase the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatThe serum concentration of Cyclophosphamide can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Pantoprazole.Approved
ParoxetineThe metabolism of Cyclophosphamide can be decreased when combined with Paroxetine.Approved, Investigational
PatupiloneCyclophosphamide may increase the cardiotoxic activities of Patupilone.Experimental, Investigational
PazopanibCyclophosphamide may increase the cardiotoxic activities of Pazopanib.Approved
PazufloxacinCyclophosphamide may increase the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinCyclophosphamide may increase the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseCyclophosphamide may increase the cardiotoxic activities of Pegaspargase.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Cyclophosphamide can be decreased when it is combined with Peginterferon alfa-2b.Approved
PembrolizumabCyclophosphamide may increase the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedCyclophosphamide may increase the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenclomedineCyclophosphamide may increase the cardiotoxic activities of Penclomedine.Investigational
PentobarbitalThe metabolism of Cyclophosphamide can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinPentostatin may increase the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Cyclophosphamide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Cyclophosphamide.Approved
PertuzumabCyclophosphamide may increase the cardiotoxic activities of Pertuzumab.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Cyclophosphamide.Experimental
Phenethyl IsothiocyanateCyclophosphamide may increase the cardiotoxic activities of Phenethyl Isothiocyanate.Investigational
PhenobarbitalThe metabolism of Cyclophosphamide can be increased when combined with Phenobarbital.Approved
Phenylacetic acidCyclophosphamide may increase the cardiotoxic activities of Phenylacetic acid.Approved
Phenylbutyric acidCyclophosphamide may increase the cardiotoxic activities of Phenylbutyric acid.Approved, Investigational
PhenytoinThe metabolism of Cyclophosphamide can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe risk or severity of adverse effects can be increased when Phosphoramidon is combined with Cyclophosphamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclophosphamide.Approved, Investigational
PinometostatCyclophosphamide may increase the cardiotoxic activities of Pinometostat.Investigational
PioglitazoneThe metabolism of Cyclophosphamide can be decreased when combined with Pioglitazone.Approved, Investigational
PipobromanCyclophosphamide may increase the cardiotoxic activities of Pipobroman.Approved
PirarubicinCyclophosphamide may increase the cardiotoxic activities of Pirarubicin.Investigational
PirfenidoneCyclophosphamide may increase the cardiotoxic activities of Pirfenidone.Approved, Investigational
PirlindoleCyclophosphamide may increase the cardiotoxic activities of Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cyclophosphamide.Approved
PixantroneCyclophosphamide may increase the cardiotoxic activities of Pixantrone.Approved, Investigational
PlevitrexedCyclophosphamide may increase the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinCyclophosphamide may increase the cardiotoxic activities of Plicamycin.Approved, Investigational, Withdrawn
PodofiloxCyclophosphamide may increase the cardiotoxic activities of Podofilox.Approved
PodophyllinCyclophosphamide may increase the cardiotoxic activities of Podophyllin.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Cyclophosphamide.Approved
PomalidomideCyclophosphamide may increase the cardiotoxic activities of Pomalidomide.Approved
PonatinibCyclophosphamide may increase the cardiotoxic activities of Ponatinib.Approved
Porfimer sodiumCyclophosphamide may increase the cardiotoxic activities of Porfimer sodium.Approved, Investigational
porfiromycinCyclophosphamide may increase the cardiotoxic activities of porfiromycin.Investigational
PosaconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateCyclophosphamide may increase the cardiotoxic activities of Pralatrexate.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cyclophosphamide.Approved
PrednimustineCyclophosphamide may increase the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneCyclophosphamide may increase the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneCyclophosphamide may increase the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Cyclophosphamide can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe risk or severity of adverse effects can be increased when Prinomastat is combined with Cyclophosphamide.Investigational
ProcarbazineCyclophosphamide may increase the cardiotoxic activities of Procarbazine.Approved
PromazineThe metabolism of Cyclophosphamide can be decreased when combined with Promazine.Approved, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Cyclophosphamide.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cyclophosphamide.Approved
PrulifloxacinCyclophosphamide may increase the cardiotoxic activities of Prulifloxacin.Investigational
PuromycinCyclophosphamide may increase the cardiotoxic activities of Puromycin.Experimental
PyrazoloacridineCyclophosphamide may increase the cardiotoxic activities of Pyrazoloacridine.Investigational
PyrimethamineThe metabolism of Cyclophosphamide can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Cyclophosphamide can be increased when it is combined with Quazepam.Approved, Illicit
QuinacrineCyclophosphamide may increase the cardiotoxic activities of Quinacrine.Approved, Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Cyclophosphamide.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Cyclophosphamide.Approved
QuinidineThe metabolism of Cyclophosphamide can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Cyclophosphamide can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Cyclophosphamide can be decreased when combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cyclophosphamide.Approved
RabusertibCyclophosphamide may increase the cardiotoxic activities of Rabusertib.Investigational
RacecadotrilThe risk or severity of adverse effects can be increased when Racecadotril is combined with Cyclophosphamide.Investigational
Radium Ra 223 DichlorideCyclophosphamide may increase the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedCyclophosphamide may increase the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Cyclophosphamide.Approved
RamucirumabCyclophosphamide may increase the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabCyclophosphamide may increase the cardiotoxic activities of Ranibizumab.Approved
RanimustineCyclophosphamide may increase the cardiotoxic activities of Ranimustine.Experimental
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
RanpirnaseCyclophosphamide may increase the cardiotoxic activities of Ranpirnase.Investigational
RegorafenibCyclophosphamide may increase the cardiotoxic activities of Regorafenib.Approved
RemikirenThe risk or severity of adverse effects can be increased when Remikiren is combined with Cyclophosphamide.Approved
ResveratrolCyclophosphamide may increase the cardiotoxic activities of Resveratrol.Approved, Experimental, Investigational
Rhodamine 6GCyclophosphamide may increase the cardiotoxic activities of Rhodamine 6G.Experimental
RidaforolimusCyclophosphamide may increase the cardiotoxic activities of Ridaforolimus.Investigational
RifabutinThe metabolism of Cyclophosphamide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cyclophosphamide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cyclophosphamide can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cyclophosphamide.Investigational
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Cyclophosphamide.Approved, Investigational
RituximabCyclophosphamide may increase the cardiotoxic activities of Rituximab.Approved
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Cyclophosphamide.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Cyclophosphamide.Approved
RolapitantThe metabolism of Cyclophosphamide can be decreased when combined with Rolapitant.Approved
RomidepsinCyclophosphamide may increase the cardiotoxic activities of Romidepsin.Approved, Investigational
RopiniroleThe metabolism of Cyclophosphamide can be decreased when combined with Ropinirole.Approved, Investigational
RoquinimexCyclophosphamide may increase the cardiotoxic activities of Roquinimex.Investigational
RosiglitazoneThe metabolism of Cyclophosphamide can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Cyclophosphamide.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Cyclophosphamide.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cyclophosphamide.Approved
RubitecanCyclophosphamide may increase the cardiotoxic activities of Rubitecan.Investigational
RucaparibCyclophosphamide may increase the cardiotoxic activities of Rucaparib.Approved, Investigational
RufloxacinCyclophosphamide may increase the cardiotoxic activities of Rufloxacin.Experimental
RuxolitinibCyclophosphamide may increase the cardiotoxic activities of Ruxolitinib.Approved
S-3304The risk or severity of adverse effects can be increased when S-3304 is combined with Cyclophosphamide.Investigational
SalirasibCyclophosphamide may increase the cardiotoxic activities of Salirasib.Investigational
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Cyclophosphamide.Approved
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Cyclophosphamide.Approved, Investigational
SaracatinibCyclophosphamide may increase the cardiotoxic activities of Saracatinib.Investigational
SargramostimThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim.Approved, Investigational
SatraplatinCyclophosphamide may increase the cardiotoxic activities of Satraplatin.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Cyclophosphamide.Approved
SecobarbitalThe metabolism of Cyclophosphamide can be increased when combined with Secobarbital.Approved, Vet Approved
SeliciclibCyclophosphamide may increase the cardiotoxic activities of Seliciclib.Investigational
SemaxanibCyclophosphamide may increase the cardiotoxic activities of Semaxanib.Investigational
SemustineCyclophosphamide may increase the cardiotoxic activities of Semustine.Experimental, Investigational
SeocalcitolCyclophosphamide may increase the cardiotoxic activities of Seocalcitol.Experimental, Investigational
SertralineThe metabolism of Cyclophosphamide can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Cyclophosphamide can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cyclophosphamide.Approved
SiltuximabThe serum concentration of Cyclophosphamide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Cyclophosphamide.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cyclophosphamide.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclophosphamide.Approved
SirolimusCyclophosphamide may increase the cardiotoxic activities of Sirolimus.Approved, Investigational
SitafloxacinCyclophosphamide may increase the cardiotoxic activities of Sitafloxacin.Experimental, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Cyclophosphamide.Approved, Investigational
SivelestatThe risk or severity of adverse effects can be increased when Sivelestat is combined with Cyclophosphamide.Investigational
SizofiranCyclophosphamide may increase the cardiotoxic activities of Sizofiran.Investigational
SoblidotinCyclophosphamide may increase the cardiotoxic activities of Soblidotin.Investigational
SonidegibCyclophosphamide may increase the cardiotoxic activities of Sonidegib.Approved, Investigational
SorafenibCyclophosphamide may increase the cardiotoxic activities of Sorafenib.Approved, Investigational
SparfloxacinCyclophosphamide may increase the cardiotoxic activities of Sparfloxacin.Approved, Investigational
Sparfosic acidCyclophosphamide may increase the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinCyclophosphamide may increase the cardiotoxic activities of Sparsomycin.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Cyclophosphamide.Approved
squalamineCyclophosphamide may increase the cardiotoxic activities of squalamine.Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cyclophosphamide.Investigational
SRT501Cyclophosphamide may increase the cardiotoxic activities of SRT501.Investigational
St. John's WortThe serum concentration of Cyclophosphamide can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Cyclophosphamide can be increased when it is combined with Stiripentol.Approved
StreptozocinCyclophosphamide may increase the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Cyclophosphamide.Approved
SulfadiazineThe metabolism of Cyclophosphamide can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Cyclophosphamide can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Cyclophosphamide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulforaphaneCyclophosphamide may increase the cardiotoxic activities of Sulforaphane.Investigational
SulindacCyclophosphamide may increase the cardiotoxic activities of Sulindac.Approved
SunitinibCyclophosphamide may increase the cardiotoxic activities of Sunitinib.Approved, Investigational
SuraminCyclophosphamide may increase the cardiotoxic activities of Suramin.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Cyclophosphamide.Approved, Investigational
TalaporfinCyclophosphamide may increase the cardiotoxic activities of Talaporfin.Investigational
TalazoparibCyclophosphamide may increase the cardiotoxic activities of Talazoparib.Investigational
TamoxifenCyclophosphamide may increase the cardiotoxic activities of Tamoxifen.Approved
TaselisibCyclophosphamide may increase the cardiotoxic activities of Taselisib.Investigational
TaurolidineCyclophosphamide may increase the cardiotoxic activities of Taurolidine.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Cyclophosphamide.Investigational
TegafurCyclophosphamide may increase the cardiotoxic activities of Tegafur.Approved
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Cyclophosphamide.Approved, Withdrawn
TelithromycinThe metabolism of Cyclophosphamide can be decreased when combined with Telithromycin.Approved
TemafloxacinCyclophosphamide may increase the cardiotoxic activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Cyclophosphamide.Experimental, Investigational
TemoporfinCyclophosphamide may increase the cardiotoxic activities of Temoporfin.Approved, Investigational
TemozolomideCyclophosphamide may increase the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusCyclophosphamide may increase the cardiotoxic activities of Temsirolimus.Approved
TeniposideCyclophosphamide may increase the cardiotoxic activities of Teniposide.Approved
TerbinafineThe metabolism of Cyclophosphamide can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Cyclophosphamide.Experimental
TeriflunomideThe metabolism of Cyclophosphamide can be decreased when combined with Teriflunomide.Approved
TestolactoneCyclophosphamide may increase the cardiotoxic activities of Testolactone.Approved, Investigational
TezacitabineCyclophosphamide may increase the cardiotoxic activities of Tezacitabine.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Cyclophosphamide.Investigational
ThalidomideCyclophosphamide may increase the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThioridazineThe metabolism of Cyclophosphamide can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiorphanThe risk or severity of adverse effects can be increased when Thiorphan is combined with Cyclophosphamide.Experimental
ThiotepaCyclophosphamide may increase the cardiotoxic activities of Thiotepa.Approved
ThymalfasinCyclophosphamide may increase the cardiotoxic activities of Thymalfasin.Approved, Investigational
TiazofurineCyclophosphamide may increase the cardiotoxic activities of Tiazofurine.Experimental
TiboloneCyclophosphamide may increase the cardiotoxic activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Cyclophosphamide can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Cyclophosphamide can be decreased when combined with Ticlopidine.Approved
TioguanineCyclophosphamide may increase the cardiotoxic activities of Tioguanine.Approved
Tiomolibdate ionCyclophosphamide may increase the cardiotoxic activities of Tiomolibdate ion.Investigational
TipifarnibCyclophosphamide may increase the cardiotoxic activities of Tipifarnib.Investigational
TipranavirThe risk or severity of adverse effects can be increased when Tipranavir is combined with Cyclophosphamide.Approved, Investigational
TirapazamineCyclophosphamide may increase the cardiotoxic activities of Tirapazamine.Investigational
TivozanibCyclophosphamide may increase the cardiotoxic activities of Tivozanib.Investigational
TocilizumabThe serum concentration of Cyclophosphamide can be decreased when it is combined with Tocilizumab.Approved
TofacitinibCyclophosphamide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolbutamideThe metabolism of Cyclophosphamide can be decreased when combined with Tolbutamide.Approved
TopiramateThe metabolism of Cyclophosphamide can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Cyclophosphamide can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanCyclophosphamide may increase the cardiotoxic activities of Topotecan.Approved, Investigational
ToremifeneCyclophosphamide may increase the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabCyclophosphamide may increase the cardiotoxic activities of Tositumomab.Approved, Investigational
ToyocamycinCyclophosphamide may increase the cardiotoxic activities of Toyocamycin.Experimental
TrabectedinCyclophosphamide may increase the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibCyclophosphamide may increase the cardiotoxic activities of Trametinib.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Cyclophosphamide.Approved
TranylcypromineThe metabolism of Cyclophosphamide can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
Trastuzumab emtansineCyclophosphamide may increase the cardiotoxic activities of Trastuzumab emtansine.Approved
TrebananibCyclophosphamide may increase the cardiotoxic activities of Trebananib.Investigational
TremelimumabCyclophosphamide may increase the cardiotoxic activities of Tremelimumab.Investigational
TreosulfanCyclophosphamide may increase the cardiotoxic activities of Treosulfan.Investigational
TretazicarCyclophosphamide may increase the cardiotoxic activities of Tretazicar.Investigational
TretinoinCyclophosphamide may increase the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TriaziquoneCyclophosphamide may increase the cardiotoxic activities of Triaziquone.Experimental
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Cyclophosphamide.Approved, Vet Approved
TrifluridineCyclophosphamide may increase the cardiotoxic activities of Trifluridine.Approved
TrilostaneCyclophosphamide may increase the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe metabolism of Cyclophosphamide can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimetrexateCyclophosphamide may increase the cardiotoxic activities of Trimetrexate.Approved, Investigational
TriptolideCyclophosphamide may increase the cardiotoxic activities of Triptolide.Investigational
TriptorelinCyclophosphamide may increase the cardiotoxic activities of Triptorelin.Approved, Vet Approved
TrofosfamideCyclophosphamide may increase the cardiotoxic activities of Trofosfamide.Investigational
TrovafloxacinCyclophosphamide may increase the cardiotoxic activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxacitabineCyclophosphamide may increase the cardiotoxic activities of Troxacitabine.Investigational
TubercidinCyclophosphamide may increase the cardiotoxic activities of Tubercidin.Experimental
UbenimexCyclophosphamide may increase the cardiotoxic activities of Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Cyclophosphamide.Approved, Experimental
UlinastatinThe risk or severity of adverse effects can be increased when Ulinastatin is combined with Cyclophosphamide.Investigational
Uracil mustardCyclophosphamide may increase the cardiotoxic activities of Uracil mustard.Approved
VadimezanCyclophosphamide may increase the cardiotoxic activities of Vadimezan.Investigational
Valproic AcidThe metabolism of Cyclophosphamide can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinCyclophosphamide may increase the cardiotoxic activities of Valrubicin.Approved
ValsartanThe metabolism of Cyclophosphamide can be decreased when combined with Valsartan.Approved, Investigational
VandetanibCyclophosphamide may increase the cardiotoxic activities of Vandetanib.Approved
VapreotideCyclophosphamide may increase the cardiotoxic activities of Vapreotide.Approved, Investigational
VeliparibCyclophosphamide may increase the cardiotoxic activities of Veliparib.Investigational
VemurafenibCyclophosphamide may increase the cardiotoxic activities of Vemurafenib.Approved
VenetoclaxCyclophosphamide may increase the cardiotoxic activities of Venetoclax.Approved
VenlafaxineThe metabolism of Cyclophosphamide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Cyclophosphamide can be decreased when combined with Verapamil.Approved
VerteporfinCyclophosphamide may increase the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneCyclophosphamide may increase the cardiotoxic activities of Vesnarinone.Investigational
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Cyclophosphamide.Approved, Investigational
VinblastineCyclophosphamide may increase the cardiotoxic activities of Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
VincristineCyclophosphamide may increase the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineCyclophosphamide may increase the cardiotoxic activities of Vindesine.Approved, Investigational
VinflunineCyclophosphamide may increase the cardiotoxic activities of Vinflunine.Approved
VinorelbineCyclophosphamide may increase the cardiotoxic activities of Vinorelbine.Approved, Investigational
VintafolideCyclophosphamide may increase the cardiotoxic activities of Vintafolide.Investigational
VismodegibCyclophosphamide may increase the cardiotoxic activities of Vismodegib.Approved
Vitamin ACyclophosphamide may increase the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Cyclophosphamide can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatCyclophosphamide may increase the cardiotoxic activities of Vorinostat.Approved, Investigational
VorozoleCyclophosphamide may increase the cardiotoxic activities of Vorozole.Experimental
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Cyclophosphamide.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Cyclophosphamide.Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe risk or severity of adverse effects can be increased when Z-Val-Ala-Asp fluoromethyl ketone is combined with Cyclophosphamide.Experimental
ZafirlukastThe metabolism of Cyclophosphamide can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Cyclophosphamide can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Cyclophosphamide.Experimental
ZorubicinCyclophosphamide may increase the cardiotoxic activities of Zorubicin.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Cyclophosphamide.Approved
ZucapsaicinThe metabolism of Cyclophosphamide can be decreased when combined with Zucapsaicin.Approved
Zuretinol acetateCyclophosphamide may increase the cardiotoxic activities of Zuretinol acetate.Investigational
Food Interactions
  • Drink liberally- 2 to 3 liters/day.
  • Take with food to reduce irritation.

References

Synthesis Reference

Riccardo Dalla-Favera, Alessandro Massimo Gianni, "Retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs." U.S. Patent US6268138, issued March, 1999.

US6268138
General References
  1. Brock N: The history of the oxazaphosphorine cytostatics. Cancer. 1996 Aug 1;78(3):542-7. [PubMed:8697402]
  2. Brock N: Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture. Cancer Res. 1989 Jan 1;49(1):1-7. [PubMed:2491747]
External Links
Human Metabolome Database
HMDB14672
KEGG Drug
D07760
KEGG Compound
C07888
PubChem Compound
2907
PubChem Substance
46505441
ChemSpider
2804
ChEBI
4027
ChEMBL
CHEMBL88
Therapeutic Targets Database
DAP000532
PharmGKB
PA449165
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Cyclophosphamide
ATC Codes
L01AA01 — Cyclophosphamide
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
MSDS
Download (76.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
0CompletedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
0CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Post Transplant Lymphoproliferative Disorder / Primary Mediastinal (Thymic) Large B-cell Lymphoma1
0RecruitingPreventionTumors, Solid1
0RecruitingTreatmentAcute Lymphoblastic Leukemia, Adult1
0RecruitingTreatmentEwing's Sarcoma (ES) / Gliomas / Neuroectodermal Tumors, Primitive / Retinoblastoma / Rhabdomyosarcomas / Sarcoma, Osteogenic / Wilms' tumor1
0RecruitingTreatmentImmunology / Radiotherapy1
0RecruitingTreatmentMelanoma (Skin) / Skin Cancers1
0RecruitingTreatmentX-Linked Chronic Granulomatious Disease1
0TerminatedTreatmentMultiple Myeloma (MM)1
0TerminatedTreatmentRelapsed or Refractory Acute Myeloid Leukemia1
0WithdrawnTreatmentCarcinoma, Non-Small-Cell-Lung / Lung Cancer Non-Small Cell Cancer (NSCLC)1
0WithdrawnTreatmentMultiple Myeloma (MM) / Myeloma-Multiple1
1Active Not RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / CD45-Positive Neoplastic Cells Present / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts1
1Active Not RecruitingTreatmentAdult Solid Neoplasm / Colorectal Adenocarcinoma / Pancreatic Adenocarcinoma Metastatic / Recurrent Breast Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Melanoma of the Skin / Recurrent Non-Small Cell Lung Carcinoma / Recurrent Pancreatic Carcinoma / Renal Cell Carcinoma Recurrent / Solid Neoplasms / Stage IV Breast Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Renal Cell Cancer / Stage IV Skin Melanoma / Stage IVA Colorectal Cancer / Stage IVA Pancreatic Cancer / Stage IVB Colorectal Cancer / Stage IVB Pancreatic Cancer1
1Active Not RecruitingTreatmentAdvanced Malignancies / Cancer, Advanced1
1Active Not RecruitingTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / B-Cell Prolymphocytic Leukemia / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia1
1Active Not RecruitingTreatmentBurkitt's Lymphoma / Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1Active Not RecruitingTreatmentCancer, Breast1
1Active Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1Active Not RecruitingTreatmentCancer, Ovarian / Peritoneal Cavity Cancer1
1Active Not RecruitingTreatmentDiffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell / Primary Mediastinal B-Cell Lymphoma1
1Active Not RecruitingTreatmentDiffuse Large B-Cell Lymphoma, Lymphoma Follicular / Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular1
1Active Not RecruitingTreatmentFallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Epithelial Cancer1
1Active Not RecruitingTreatmentHER2/Neu Negative / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v7 / Stage IIIC Breast Cancer / Stage IIIC Breast Cancer AJCC v7 / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v71
1Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
1Active Not RecruitingTreatmentLeukemias2
1Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
1Active Not RecruitingTreatmentLymphocytic Leukemia, Chronic1
1Active Not RecruitingTreatmentMalignant Lymphomas1
1Active Not RecruitingTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
1Active Not RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
1Active Not RecruitingTreatmentMyeloma, Plasma-Cell / Myeloma-Multiple1
1Active Not RecruitingTreatmentNeuroblastomas4
1Active Not RecruitingTreatmentProstate Cancer1
1Active Not RecruitingTreatmentRecurrent Breast Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Stage IIA Breast Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Breast Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Breast Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Breast Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Breast Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer1
1Active Not RecruitingTreatmentSolid Neoplasms / Stage III Non-Hodgkin Lymphoma / Stage IV Non-Hodgkin Lymphoma1
1Active Not RecruitingTreatmentTriple Negative Breast Neoplasms1
1CompletedPreventionLeukemias / Multiple Myeloma (MM)1
1CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Leukemia, Prolymphocytic / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myelogenous Leukemia (CML) / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
1CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
1CompletedTreatmentAdrenocortical Carcinoma / Carcinoid tumour of the gastrointestinal tract / Neuroblastomas / Renal Cancers / Retinoblastoma / Sarcomas1
1CompletedTreatmentAdult Liposarcoma / Adult Synovial Sarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
1CompletedTreatmentAdvanced Cancers / Leukemias1
1CompletedTreatmentAdvanced Neoplasm1
1CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentCancer, Breast6
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Malignant Neoplasm of Colon / Prostate Cancer / Renal Cancers1
1CompletedTreatmentCancer, Breast / Malignant Melanoma1
1CompletedTreatmentCancer, Breast / Nausea and Vomiting1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Carcinoma / Primary Peritoneal Carcinoma1
1CompletedTreatmentCancers2
1CompletedTreatmentCancers / Leukemias1
1CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Neoplasms, Colorectal1
1CompletedTreatmentCardiac Toxicity / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChildhood Solid Tumors / Malignant Solid Tumours1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
1CompletedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Small Intestine Cancer1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases1
1CompletedTreatmentCongenital Hypoplastic Anemia1
1CompletedTreatmentDisseminated Sclerosis2
1CompletedTreatmentEnd-Stage Renal Disease (ESRD) / Impaired Renal Function / Nephritis, Lupus / Systemic Lupus Erythematosus (SLE)1
1CompletedTreatmentEpithelial Malignancies / Melanoma / Pleural Malignancy / Sarcomas1
1CompletedTreatmentEsophageal Cancers / Lung Cancers / Malignant Pleural Mesothelioma (MPM) / Sarcomas / Thymic Carcinoma1
1CompletedTreatmentEwing's Sarcoma (ES)1
1CompletedTreatmentGastrointestinal Metastatic Cancer1
1CompletedTreatmentHer2-Positive Breast Cancer / Recurrent Breast Cancer / Recurrent Non-small Cell Lung Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Stage IV Breast Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor1
1CompletedTreatmentHodgkins Disease (HD) / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphoblastic, Acute1
1CompletedTreatmentLeukemias2
1CompletedTreatmentLeukemias / Malignant Lymphomas2
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Plasma Cell Neoplasms1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes2
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases2
1CompletedTreatmentLeukemias / Myelodysplastic Syndrome1
1CompletedTreatmentLeukemias / Refractory Solid Tumors1
1CompletedTreatmentLung Cancers1
1CompletedTreatmentLung Cancers / Mesothelioma, Malignant1
1CompletedTreatmentLymphoblastic Leukemia, Acute, Childhood1
1CompletedTreatmentLymphocytic Leukemia, Chronic1
1CompletedTreatmentLymphoma, Large-Cell, Anaplastic / Lymphoma, NK-cell / T-Cell Lymphomas1
1CompletedTreatmentMalignant (Pleural) Mesothelioma1
1CompletedTreatmentMalignant Lymphomas2
1CompletedTreatmentMalignant Lymphomas / Neoplasms1
1CompletedTreatmentMelanoma2
1CompletedTreatmentMelanoma (Skin)3
1CompletedTreatmentMelanoma / Neuroblastomas / Sarcoma, Osteogenic / Sarcomas1
1CompletedTreatmentMetastatic Breast Cancer (MBC)1
1CompletedTreatmentMultiple Myeloma (MM)3
1CompletedTreatmentNY-ESO-1-expressing Tumors1
1CompletedTreatmentNeoplams, Advanced / Neoplasms, Advanced1
1CompletedTreatmentNeoplasms, Brain / Neuroblastomas / Sarcomas / Tumors, Central Nervous System1
1CompletedTreatmentNeuroblastomas3
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
1CompletedTreatmentOsteogenesis Imperfecta1
1CompletedTreatmentOvarian Cancer Metastatic1
1CompletedTreatmentPeripheral T-Cell Lymphoma (PTCL)1
1CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma2
1CompletedTreatmentRecurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentSclerosis, Progressive Systemic1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific2
1Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Immune System Diseases / Immunoproliferative Disorders1
1Not Yet RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / B-cell Adult Acute Lymphoblastic Leukemia / B-Cell Chronic Lymphocytic Leukemia / Hematopoietic/Lymphoid Cancer / Refractory Chronic Lymphocytic Leukemia1
1Not Yet RecruitingTreatmentCD19 Positive Malignant B-cell Leukemia and Lymphoma1
1Not Yet RecruitingTreatmentCancer of Breast / Cancer, Breast1
1Not Yet RecruitingTreatmentFallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Cancer / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
1Not Yet RecruitingTreatmentGastrointestinal Cancer Metastatic1
1Not Yet RecruitingTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders / Thalassaemic disorders1
1Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
1Not Yet RecruitingTreatmentHormone Refractory Prostate Cancer1
1Not Yet RecruitingTreatmentInvasive Bladder Cancer Stage IV1
1Not Yet RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Relapsed/Refractory Acute Myeloid Leukemia1
1Not Yet RecruitingTreatmentMetastatic Renal Cell Carcinoma1
1Not Yet RecruitingTreatmentNeuroblastomas2
1Not Yet RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
1Not Yet RecruitingTreatmentPlatinum Resistant Ovarian Cancer1
1Not Yet RecruitingTreatmentT-cell Acute Lymphoblastic Leukemia / T-cell Acute Lymphoblastic Lymphoma / T-non-Hodgkin Lymphoma1
1Not Yet RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / B-cell Adult Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B-cell Adult Acute Lymphoblastic Leukemia / Lymphoma, Lymphoblastic / T-cell Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Burkitt's Lymphoma1
1RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Adult Acute Lymphoblastic Leukemia in Complete Remission / Childhood Acute Lymphoblastic Leukemia in Complete Remission / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
1RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Malignant Lymphomas1
1RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentAdenocarcinoma of the Prostate1
1RecruitingTreatmentAdenocarcinomas / Advanced NSCLC / Carcinoma, Adenosquamous / Lung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Non-Small Cell Lung Cancer / Squamous Cell Carcinoma (SCC)1
1RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) / Donor / Early Relapse of Acute Myeloid Leukemia / Late Relapse of Acute Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
1RecruitingTreatmentAdult B Acute Lymphoblastic Leukemia / BCL2 Gene Rearrangement / BCL6 Gene Rearrangement / CD19 Positive / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / MYC Gene Rearrangement / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Adult Acute Lymphoblastic Leukemia / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma1
1RecruitingTreatmentAdult Solid Neoplasm / Childhood Solid Neoplasm / Neoplasms, Metastatic1
1RecruitingTreatmentAdvanced Cancers1
1RecruitingTreatmentAdvanced Ovarian Cancer / Malignant Melanoma1
1RecruitingTreatmentAdvanced or Unresectable Melanoma Progressing After PD1 Blockade1
1RecruitingTreatmentAgnogenic Myeloid Metaplasia / Leukemias / Malignant Lymphomas / Smith-Magenis Syndrome1
1RecruitingTreatmentAnal Carcinoma / Cervical Cancers / Oropharyngeal Cancers / Penile Cancer / Vaginal Cancers1
1RecruitingTreatmentAnaplastic Oligodendroglioma of Brain (Diagnosis) / Astrocytomas / Ependymomas / Ganglioglioma / Malignant Astrocytoma / Malignant Glioma of Brain / Mixed Oligo-Astrocytoma / Oligodendrogliomas / Pylocytic/Pylomyxoid Astrocytoma1
1RecruitingTreatmentAplastic Anaemia (AA) / Chronic Leukemias / Congenital Hematological Disorder / Immune Deficiency Disorder / Leukaemia, Acute / Malignant Lymphomas / Metabolism Disorder / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Tumors, Solid1
1RecruitingTreatmentB Acute Lymphoblastic Leukemia / CD19 Positive / Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly / Minimal Residual Disease / Philadelphia Chromosome Positive / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma / T-Cell/Histiocyte-Rich Large B-Cell Lymphoma1
1RecruitingTreatmentB-cell Acute Lymphoblastic Leukemia1
1RecruitingTreatmentBCL2 Gene Rearrangement / BCL6 Gene Rearrangement / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / High-Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / MYC Gene Rearrangement / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma1
1RecruitingTreatmentBladder Cancers / Cancer, Ovarian / Esophageal Cancers / Liver Cancer / Lung Cancers / Melanoma / NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients / Synovial Sarcoma1
1RecruitingTreatmentBladder Carcinoma / Cancer, Breast / Cancer, Ovarian / Esophagus Carcinoma / Lung Cancers / Melanoma / Multiple Myeloma (MM) / Neuroblastomas / Other Metastatic Solid Cancers / Synovial Sarcoma1
1RecruitingTreatmentBreast Neoplasm, Male / Neoplasms, Breast1
1RecruitingTreatmentCD20 Positive / HIV Positivity / Lymphoma, AIDS Related / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
1RecruitingTreatmentCD52 Positive Non-Hodgkin Lymphoma / DLBCL or High-grade B-cell Lymphoma NOS / High-grade B-cell Lymphoma / Non Hodgkin Lymphoma (NHL)1
1RecruitingTreatmentCancer, Breast / Cancer, Ovarian / Esophageal Cancers / Liver Cancer / Melanoma / Sarcoma, Bone / Soft Tissue Sarcoma (STS) / Thyroid Cancers1
1RecruitingTreatmentCancer, Breast / Lung Cancers / Malignant Pleural Disease / Mesothelioma / Metastases1
1RecruitingTreatmentCancer, Breast / Malignant Neoplasm of Stomach1
1RecruitingTreatmentCancer, Breast / Metastatic HER2-negative Breast1
1RecruitingTreatmentCancers / Head and Neck Squamous Cell Carcinoma (HNSCC) / Squamous Cell Non-small Cell Lung Cancer / Tumors, Solid1
1RecruitingTreatmentCancers / Tumors, Solid1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
1RecruitingTreatmentClear Cell Sarcoma of Soft Tissue / Ewing's Sarcoma (ES) / Germ Cell Tumors / Hepatoblastomas / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas / Renal Cell Adenocarcinoma / Retinoblastoma / Rhabdoid Tumors / Rhabdomyosarcomas / Sarcoma, Osteogenic / Wilms' tumor1
1RecruitingTreatmentComposite Lymphoma / Grade 3b Follicular Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Follicular Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Follicular Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Follicular Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Follicular Lymphoma1
1RecruitingTreatmentContiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentEnteropathy-Associated T-Cell Lymphoma / Hodgkins Disease (HD) / Lymphoma, Extranodal NK-T-Cell / Lymphoma, Hodgkins / Lymphoma, Large-Cell, Anaplasitc1
1RecruitingTreatmentEwing's Sarcoma (ES) / Neuroblastomas / Recurrent or Refractory Solid Tumors / Rhabdomyosarcomas / Sarcoma, Osteogenic1
1RecruitingTreatmentFallopian Tube Cancer / High Grade Serous Ovarian Cancer / Primary Peritoneal Cancer / Tumors, Solid1
1RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentGlioblastoma Multiforme2
1RecruitingTreatmentHER2 Positive Breast Cancers / Her2-negative Metastatic Breast Cancer / HER2-positive Metastatic Breast Cancer / Locally Advanced or Early Breast Cancer1
1RecruitingTreatmentHaematological Malignancies / Plasma Cell Myeloma1
1RecruitingTreatmentHematopoietic/Lymphoid Cancer / Leukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentHigh Grade B-cell Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentHigh-Risk / Neuroblastomas1
1RecruitingTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL) / Severe Chronic Active Epstein Barr Virus / T/NK-lymphoproliferative Disease1
1RecruitingTreatmentHuman Papillomavirus Positive Anal Carcinoma / Human Papillomavirus Positive Cervical Carcinoma / Human Papillomavirus Positive Oropharyngeal Carcinoma / Human Papillomavirus Positive Penile Carcinoma / Human Papillomavirus Positive Vulvar Carcinoma / Human Papillomavirus-Related Carcinoma1
1RecruitingTreatmentInflammatory carcinoma of the breast1
1RecruitingTreatmentLeukaemia, Lymphoblastic / Lymphoma, Lymphoblastic1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)2
1RecruitingTreatmentLeukemia, B-Cell / Lymphoma, B-Cell / Lymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)2
1RecruitingTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
1RecruitingTreatmentLeukemias2
1RecruitingTreatmentLeukemias / Malignant Lymphomas1
1RecruitingTreatmentLeukemias / Pediatric Leukemia / Pediatric Solid Tumors1
1RecruitingTreatmentLeukemias / Refractory Solid Tumors / Relapsed Solid Tumors1
1RecruitingTreatmentLung Cancer, Nonsmall Cell, Recurrent1
1RecruitingTreatmentLung Squamous Cell Carcinoma1
1RecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)1
1RecruitingTreatmentLymphoma, B Cell1
1RecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentMelanoma2
1RecruitingTreatmentMelanoma and Other Malignant Neoplasms of Skin1
1RecruitingTreatmentMetastatic Colorectal Cancers1
1RecruitingTreatmentMetastatic Melanoma1
1RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
1RecruitingTreatmentMetastatic Renal Cell Carcinoma1
1RecruitingTreatmentMultiple Myeloma (MM)2
1RecruitingTreatmentNeoplasms1
1RecruitingTreatmentNeuroblastomas2
1RecruitingTreatmentProstate Cancer3
1RecruitingTreatmentRecurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1RecruitingTreatmentRecurrent Epithelial Ovarian Cancer / Recurrent Fallopian Tube Cancer / Recurrent Peritoneal Cancer1
1RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / TNFRSF17 Positive1
1RecruitingTreatmentRecurrent, Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer1
1RecruitingTreatmentRelapsed or Refractory B-cell Lymphoma1
1RecruitingTreatmentRelapsed or Refractory Neuroblastoma1
1RecruitingTreatmentSarcomas1
1RecruitingTreatmentSecondary Myelofibrosis1
1RecruitingTreatmentSickle Cell Disorders1
1RecruitingTreatmentSystemic Lupus Erythematosus (SLE)1
1RecruitingTreatmentTumors, Solid3
1RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Recurrent Pediatric ALL / Refractory Pediatric ALL / Relapsed Pediatric ALL1
1TerminatedTreatmentAplastic Anaemia (AA)1
1TerminatedTreatmentBone Cancer / Kidney Tumors / Neoplasms / Neuroblastomas / Tumors, Solid1
1TerminatedTreatmentBone Marrow Suppression / Brain and Central Nervous System Tumors / Drug/Agent Toxicity by Tissue/Organ / Long-Term Effects Secondary to Cancer Therapy in Children1
1TerminatedTreatmentCancer, Breast / Cancer, Ovarian / Colorectal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Lymphocytic, Chronic, B-Cell / Small Lymphocytic Lymphoma (SLL)1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma1
1TerminatedTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage IV Renal Cell Cancer1
1TerminatedTreatmentEpithelial Malignancies / Melanoma / Pleural Malignancy / Sarcomas1
1TerminatedTreatmentFollicular Lymphoma (FL)1
1TerminatedTreatmentGlioblastomas1
1TerminatedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Secondary Myelofibrosis1
1TerminatedTreatmentHead and Neck Carcinoma1
1TerminatedTreatmentJuvenile Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1TerminatedTreatmentLeukemias / Malignant Lymphomas / Plasma Cell Myeloma1
1TerminatedTreatmentMelanoma / Metastatic Cancers1
1TerminatedTreatmentMetastatic Cancers / Metastatic Melanoma / Metastatic Renal Cancer1
1TerminatedTreatmentNeoplasms, Kidney1
1TerminatedTreatmentRenal Cancers1
1TerminatedTreatmentScleroderma / Sclerosis, Progressive Systemic1
1TerminatedTreatmentStage IV Melanoma1
1TerminatedTreatmentStages II-III Breast Cancer1
1Unknown StatusSupportive CareChronic Myeloproliferative Disorders / Drug/Agent Toxicity by Tissue/Organ / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
1Unknown StatusTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Promyelocytic Leukemia (APL) / Agnogenic Myeloid Metaplasia / Chronic Myelogenous Leukemia (CML) / Chronic Myelomonocytic Leukemia / Juvenile Myelomonocytic Leukemia / Leukaemia, Acute / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Myeloproliferative Disorders1
1Unknown StatusTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Liver Cancer / Neuroblastomas / Sarcomas / Testicular germ cell tumour1
1Unknown StatusTreatmentCancer, Breast1
1Unknown StatusTreatmentColorectal Cancers / Metastatic Cancers1
1Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
1Unknown StatusTreatmentMelanoma (Skin)1
1Unknown StatusTreatmentSystemic Lupus Erythematosus (SLE)1
1Unknown StatusTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1WithdrawnBasic ScienceNon-small Cell Lung Cancer (NSCLC) Stage III1
1WithdrawnTreatmentAdult Synovial Sarcoma / Myxoid/Round Cell Liposarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
1WithdrawnTreatmentBlood And Marrow Transplantation / Leukemias / Malignant Lymphomas1
1WithdrawnTreatmentCancer, Breast1
1WithdrawnTreatmentCancer, Breast / Lung Cancers / Melanoma (Skin) / Renal Cancers / Testicular germ cell tumour1
1WithdrawnTreatmentCutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides and Sezary Syndrome / Stage IIB Mycosis Fungoides and Sezary Syndrome / Stage IIIA Mycosis Fungoides and Sezary Syndrome / Stage IIIB Mycosis Fungoides and Sezary Syndrome / Stage IVA Mycosis Fungoides and Sezary Syndrome / Stage IVB Mycosis Fungoides and Sezary Syndrome1
1WithdrawnTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma (SCC)1
1WithdrawnTreatmentHer2-Positive Breast Cancer / Male Breast Cancer / Stage IV Breast Cancer1
1WithdrawnTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
1WithdrawnTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1WithdrawnTreatmentMelanoma / Sarcomas1
1WithdrawnTreatmentMetastatic Melanoma1
1, 2Active Not RecruitingPreventionHaematological Malignancies1
1, 2Active Not RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / CD20 Positive / Grade 3b Follicular Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Plasmablastic Lymphoma / Primary Effusion Lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1, 2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Previously Treated Myelodysplastic Syndromes / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Indolent Adult Non-Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Plasma Cell Myeloma / Refractory Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Mesothelioma / Neoplasms, Pancreatic1
1, 2Active Not RecruitingTreatmentAdult T-Cell Leukemia (ATL)1
1, 2Active Not RecruitingTreatmentAdvanced Pleural Malignant Mesothelioma / HLA-A*0201 Positive Cells Present / Recurrent Non-Small Cell Lung Carcinoma / Recurrent Pleural Malignant Mesothelioma / Stage III Non-Small Cell Lung Cancer / Stage III Pleural Mesothelioma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pleural Mesothelioma1
1, 2Active Not RecruitingTreatmentAlemtuzumab (Campath ) / Graft Versus Host Disease (GVHD) / Peripheral Blood Stem Cell Transplantation / Sickle Cell Disorders / Sirolimus (Rapamune )1
1, 2Active Not RecruitingTreatmentCancer of the Prostate / Metastatic Hormone Refractory Prostate Cancer / Prostate Cancer1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Recurrent Breast Cancer1
1, 2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma1
1, 2Active Not RecruitingTreatmentColorectal Cancers1
1, 2Active Not RecruitingTreatmentHer2-Positive Breast Cancer / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
1, 2Active Not RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Refractory Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia1
1, 2Active Not RecruitingTreatmentLeukemias2
1, 2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
1, 2Active Not RecruitingTreatmentLymphoma, B-Cell, Non-Hodgkin's Lymphoma / Non Hodgkin Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas3
1, 2Active Not RecruitingTreatmentMetastatic Cancers1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)3
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Active Not RecruitingTreatmentNeuroblastomas1
1, 2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentProstate Cancer Adenocarcinoma in Situ1
1, 2Active Not RecruitingTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Smoldering Multiple Myeloma (SMM) / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Active Not RecruitingTreatmentStage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2CompletedDiagnosticSystemic Lupus Erythematosus (SLE)1
1, 2CompletedSupportive CareCancer, Breast / Drug/Agent Toxicity by Tissue/Organ1
1, 2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Myelodysplastic Syndrome1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Relapsed Leukemia1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Burkitt's Lymphoma / Lymphoma, Lymphoblastic1
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
1, 2CompletedTreatmentAcute Undifferentiated Leukemia (AUL) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / L1 Adult Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Adult Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentAdult T-cell lymphomas/leukaemias1
1, 2CompletedTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T Cell Lymphoma / Cutaneous T Cell Lymphomas (CTCL) / Peripheral T Cell Lymphoma Unspecified1
1, 2CompletedTreatmentAplastic Anaemia (AA)3
1, 2CompletedTreatmentAplastic Anaemia (AA) / Neutropenias / Pancytopenia / Severe Aplastic Anemia (SAA)2
1, 2CompletedTreatmentCancer, Breast5
1, 2CompletedTreatmentCancer, Breast / Cancer, Ovarian / Leukemias / Malignant Lymphomas / Neuroblastomas / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentCancer, Breast / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Renal Cancers1
1, 2CompletedTreatmentCancer, Breast / Male Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
1, 2CompletedTreatmentCancer, Breast / Neutropenias1
1, 2CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
1, 2CompletedTreatmentCarcinoma, Colorectal1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias / Malignant Lymphomas1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentCongenital Hypoplastic Anemia1
1, 2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell1
1, 2CompletedTreatmentGlomerulosclerosis, Focal Segmental1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD)1
1, 2CompletedTreatmentHer2-Positive Breast Cancer / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentHodgkins Disease (HD) / Malignant Lymphomas1
1, 2CompletedTreatmentInfection NOS / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2CompletedTreatmentLeukemias2
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas3
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
1, 2CompletedTreatmentLupus Erythematosus, Systemic / Nephritis, Lupus1
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse1
1, 2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2CompletedTreatmentMalignancies, Hematologic2
1, 2CompletedTreatmentMalignant Lymphomas5
1, 2CompletedTreatmentMalignant Lymphomas / Non Hodgkin Lymphoma (NHL)1
1, 2CompletedTreatmentMalignant Melanoma Stage IV1
1, 2CompletedTreatmentMelanoma1
1, 2CompletedTreatmentMelanoma (Skin)2
1, 2CompletedTreatmentMetastatic Cancers / Metastatic Melanoma / Renal Cancers1
1, 2CompletedTreatmentMultiple Myeloma (MM)6
1, 2CompletedTreatmentOvarian Epithelial Cancer1
1, 2CompletedTreatmentPlasma Cell Myeloma1
1, 2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma2
1, 2No Longer AvailableNot AvailableMelanoma (Skin)1
1, 2Not Yet RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2Not Yet RecruitingTreatmentAdvanced Malignant Solid Tumor1
1, 2Not Yet RecruitingTreatmentAntibodies, Neoplasm1
1, 2Not Yet RecruitingTreatmentBreast Neoplasm Female / Malignant Neoplasm of Female Breast1
1, 2Not Yet RecruitingTreatmentCancer, Ovarian1
1, 2Not Yet RecruitingTreatmentColorectal Cancers1
1, 2Not Yet RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1, 2Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
1, 2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Not Yet RecruitingTreatmentMalignant Neoplasm of Breast1
1, 2Not Yet RecruitingTreatmentMelanoma1
1, 2Not Yet RecruitingTreatmentNeuroendocrine Carcinoma of the Skin1
1, 2Not Yet RecruitingTreatmentNon Hodgkin Lymphoma (NHL)1
1, 2Not Yet RecruitingTreatmentStage IV Adult Hodgkin Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Gastric Carcinoma / Stage IV Nasopharyngeal Carcinoma / T-cell lymphoma stage IV1
1, 2Not Yet RecruitingTreatmentTransitional Cell Carcinoma1
1, 2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentALK- Anaplastic Large Cell Lymphoma (ALCL) / ALK- Anaplastic Largecell Lymphoma (ALCL) / Angioimmunoblastic T-cell Lymphoma (AITL) / Peripheral T-Cell Lymphoma (PTCL) / Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS) / PTCL-NOS1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Burkitt's Lymphoma / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Gray Zone Lymphoma / Juvenile Myelomonocytic Leukemia / Lymphoma, Hodgkins / Lymphoma, Large Cell / Lymphoma, Mantle-Cell / Lymphoma,Non-Hodgkin / Marginal Zone Lymphoma / Myelodysplastic Syndromes1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myeloid Leukemia (CML) / Juvenile Myelomonocytic Leukemia (JMML) / Lymphoma (Hodgkin's and Non-Hodgkin's) / Myelodysplastic Syndromes (MDS)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
1, 2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / B-lymphoid Malignancies / Chronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Myelodysplastic Syndrome / Childhood Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia1
1, 2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / B-cell Adult Acute Lymphoblastic Leukemia / B-Cell Chronic Lymphocytic Leukemia / Hematopoietic/Lymphoid Cancer / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Chronic Lymphocytic Leukemia / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma1
1, 2RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentAdult Solid Neoplasm1
1, 2RecruitingTreatmentAdvanced or Metastatic Colorectal Cancer (CRC) / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor / Advanced or Metastatic Solid Tumors / Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous) / Pancreatic Ductal Adenocarcinoma (PDAC)1
1, 2RecruitingTreatmentAmyloidosis / Plasma Cell Myeloma1
1, 2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage II Angioimmunoblastic T-cell Lymphoma / Stage II Enteropathy-Associated T-Cell Lymphoma / Stage III Angioimmunoblastic T-cell Lymphoma / Stage III Enteropathy-Associated T-Cell Lymphoma / Stage IV Angioimmunoblastic T-cell Lymphoma / Stage IV Enteropathy-Associated T-Cell Lymphoma1
1, 2RecruitingTreatmentB-cell Acute Lymphocytic Leukemia1
1, 2RecruitingTreatmentBladder Cancers / Cancer, Breast / Cervical Cancers / Malignant Melanoma / Melanoma / Metastatic Cancer That Express the MAGE-A3-HLA A01 Antigen / Metastatic Cancers / Metastatic Melanoma That Express the MAGE-A3-HLA A01 Antigen / Oesophageal Carcinoma / Renal Cancers / Sarcomas / Urothelial Cancer1
1, 2RecruitingTreatmentBrain Cancer / Glioblastomas / Malignant Gliomas1
1, 2RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Positive / HER2/Neu Negative / Recurrent Breast Carcinoma / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2RecruitingTreatmentBreastcancer / Neoplasms, Breast1
1, 2RecruitingTreatmentCD20 Positive / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Refractory Transformed Indolent Lymphoma1
1, 2RecruitingTreatmentCancer, Breast / Cancer, Ovarian / CD70 Expressing Cancers / Malignant Neoplasm of Pancreas / Melanoma / Renal Cell Adenocarcinoma1
1, 2RecruitingTreatmentCancer of Anus / Cancer of Cervix / Cancer of Head and Neck1
1, 2RecruitingTreatmentCancer, Breast1
1, 2RecruitingTreatmentCancer, Breast / Soft-Tissue Sarcoma / Tumors, Solid1
1, 2RecruitingTreatmentCancers1
1, 2RecruitingTreatmentChildren, Adolescents and Young Adults With Refractory or Recurrent Malignancies1
1, 2RecruitingTreatmentCongenital Hypoplastic Anemia1
1, 2RecruitingTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2RecruitingTreatmentCrohn's Disease (CD)1
1, 2RecruitingTreatmentGastrointestinal Cancers / Malignant Neoplasm of Colon / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Rectal Carcinoma1
1, 2RecruitingTreatmentGraft Versus Host Disease (GVHD) / Sickle Cell Disorders / Thalassaemic disorders / Transplantation, Stem Cell1
1, 2RecruitingTreatmentHaploidentical Hematopoietic Stem Cell Transplantation / Malignant Diseases / Non-malignant Diseases1
1, 2RecruitingTreatmentHepatocellular,Carcinoma1
1, 2RecruitingTreatmentHigh-risk Medulloblastoma1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
1, 2RecruitingTreatmentLeukemias / Malignant Lymphomas1
1, 2RecruitingTreatmentLeukemias / Myeloproliferative Disorders1
1, 2RecruitingTreatmentLymphoma, B Cell1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas3
1, 2RecruitingTreatmentMelanoma2
1, 2RecruitingTreatmentMetastatic Melanoma2
1, 2RecruitingTreatmentMultiple Myeloma (MM)3
1, 2RecruitingTreatmentMyelodysplastic Syndromes1
1, 2RecruitingTreatmentMyeloproliferative Disorders / Primary Myelofibrosis1
1, 2RecruitingTreatmentNeutropenias1
1, 2RecruitingTreatmentOvarian Cancer Metastatic1
1, 2RecruitingTreatmentPlasma Cell Leukemia in Remission / Plasma Cell Myeloma1
1, 2RecruitingTreatmentPleural Mesotheliomas1
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2RecruitingTreatmentScleroderma, Systemic / Severe Systemic Sclerosis1
1, 2RecruitingTreatmentSickle Cell Disorders1
1, 2RecruitingTreatmentSynovial Sarcoma1
1, 2RecruitingTreatmentT Cell Non-Hodgkin's Lymphoma1
1, 2RecruitingTreatmentTo Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy1
1, 2RecruitingTreatmentTreatments1
1, 2SuspendedTreatmentCancer, Breast / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2SuspendedTreatmentEsophageal Cancers / Lung Cancers / Malignant Pleural Mesothelioma (MPM) / Sarcomas / Thymic Carcinoma1
1, 2TerminatedTreatmentAnemias / Immunodeficiencies / Leukemias / Malignant Lymphomas / Neuroblastomas1
1, 2TerminatedTreatmentCancer, Breast1
1, 2TerminatedTreatmentCancer, Ovarian1
1, 2TerminatedTreatmentCongenital Hypoplastic Anemia1
1, 2TerminatedTreatmentGlioblastoma Multiforme1
1, 2TerminatedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2TerminatedTreatmentGraft Versus Host Disease (GVHD) / Lupus Erythematosus1
1, 2TerminatedTreatmentLeukemias / Malignant Lymphomas1
1, 2TerminatedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes1
1, 2TerminatedTreatmentMalignant Lymphomas1
1, 2TerminatedTreatmentMalignant Melanoma / Melanoma / Melanoma, Experimental1
1, 2TerminatedTreatmentMetastatic Cancers1
1, 2TerminatedTreatmentMetastatic Cancers / Metastatic Melanoma / Metastatic Renal Cancer1
1, 2TerminatedTreatmentMetastatic Melanoma / Skin Cancers2
1, 2TerminatedTreatmentNeoplasm Metastases / Neoplasms, Breast1
1, 2TerminatedTreatmentProstate Cancer1
1, 2TerminatedTreatmentRecurrent Melanoma / Stage IV Melanoma1
1, 2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2TerminatedTreatmentRelapsed T-Cell Acute Lymphoblastic Leukemia / Relapsed T-Cell Lymphoblastic Lymphoma1
1, 2Unknown StatusTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer1
1, 2Unknown StatusTreatmentAmyloidosis1
1, 2Unknown StatusTreatmentCancer, Breast6
1, 2Unknown StatusTreatmentCancer, Breast / Cancer, Ovarian / Colorectal Cancers / Liver Cancer / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Melanoma (Skin) / Metastatic Cancers1
1, 2Unknown StatusTreatmentLeukaemia, Acute / Myelodysplastic Syndrome / Tumors, Solid1
1, 2Unknown StatusTreatmentMalignant Lymphomas3
1, 2Unknown StatusTreatmentMalignant Melanoma1
1, 2Unknown StatusTreatmentMantle Cell Lymphoma Recurrent1
1, 2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2WithdrawnNot AvailableCancer, Ovarian / Primary Peritoneal Cancer1
1, 2WithdrawnTreatmentAcute Lymphocytic Leukemia (ALL) / Anemia, Refractory, With Excess of Blasts / Burkitt's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia in Blast Crisis / Chronic Myeloproliferative Disease / Follicular Lymphoma (FL) / High Grade Non-Hodgkin's Lymphoma / Large Cell Non-Hodgkin's Lymphoma / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Lymphoblastic / Lymphoma, Mantle-Cell / Lymphoplasmacytic Lymphoma / Malignancies, Hematologic / Marginal Zone B-Cell Lymphoma / Prolymphocytic Lymphoma / Small Lymphocytic Lymphoma (SLL)1
1, 2WithdrawnTreatmentCancer, Breast1
1, 2WithdrawnTreatmentLarge Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease / Primary Effusion Lymphomas1
1, 2WithdrawnTreatmentLarge-Cell Lymphoma, Diffuse / Lymphoma, Diffuse Large-Cell / Lymphoma, Diffuse Large-Cell B-cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2WithdrawnTreatmentLeukemias1
1, 2WithdrawnTreatmentMetastatic Thyroid Cancer1
1, 2WithdrawnTreatmentMyeloma Multiple1
2Active Not RecruitingBasic ScienceStage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Active Not RecruitingOtherCancer, Breast / Locally Advanced Malignant Neoplasm1
2Active Not RecruitingPreventionChronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukaemia, Acute / Lymphoma, B-Cell / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Myelodysplasia / Small Lymphocytic Lymphoma (SLL)1
2Active Not RecruitingSupportive CareLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome RAEB 1 / Myelodysplastic Syndrome RAEB 21
2Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Immune System Diseases / Leukemia Acute Myeloid Leukemia (AML) / Malignant Lymphomas / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAcute myeloid leukaemia (in remission) / Congenital Hypoplastic Anemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentAdrenoleukodystrophy (ALD) / Alpha Mannosidosis / Aspartylglucosaminuria / Fucosidosis / Hunter Syndrome / Hurler's Syndrome / Krabbe's Disease / Metachromatic Leukodystrophy (MLD) / Mucopolysaccharidosis / Mucopolysaccharidosis VI / Peroxisomal Disorders / Sly Syndrome / Sphingolipidoses1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAntibody Mediated Rejection1
2Active Not RecruitingTreatmentB-cell Lymphoid Leukemia / Young Patients1
2Active Not RecruitingTreatmentCD20 Positive / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
2Active Not RecruitingTreatmentCLL (Chronic Lymphocytic Leukemia) / Small Lymphocytic Lymphoma (SLL)1
2Active Not RecruitingTreatmentCancer, Breast17
2Active Not RecruitingTreatmentCancer, Breast / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage III Breast Cancer1
2Active Not RecruitingTreatmentChronic Granulomatous Disease (CGD)1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias2
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Low-Grade / Lymphoma, Mantle-Cell / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Ewing Sarcoma of Bone or Soft Tissue / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Active Not RecruitingTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentFallopian Tube Cancer / Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2Active Not RecruitingTreatmentFollicular Lymphoma, Grade 3b / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Transformed Lymphoma / DLBCL1
2Active Not RecruitingTreatmentGATA2 / Immunodeficiencies / Smith-Magenis Syndrome1
2Active Not RecruitingTreatmentHematopoietic/Lymphoid Cancer1
2Active Not RecruitingTreatmentHemoglobinuria, Paroxysmal Nocturnal (PNH) / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Acute Lymphocytic (ALL) / Leukemia, Myeloid, Chronic(CML) / Lymphoma, Hodgkins / Lymphoma, Non-Hodgkin (NHL) / Myelodysplastic Syndromes (MDS)1
2Active Not RecruitingTreatmentHigh Risk Neuroblastoma1
2Active Not RecruitingTreatmentHodgkins Disease (HD)1
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Leukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentInflammatory carcinoma of the breast / Male Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Active Not RecruitingTreatmentJuvenile Myelomonocytic Leukemia1
2Active Not RecruitingTreatmentLeukaemia, Lymphoblastic / Lymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphocytic, Acute / Leukemia, Lymphocytic, Chronic / Leukemia,Myeloid, Chronic / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
2Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2Active Not RecruitingTreatmentLeukemias4
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas2
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Plasma Cell Neoplasms / Renal Cancers1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Transplantation, Stem Cell1
2Active Not RecruitingTreatmentLung Cancers1
2Active Not RecruitingTreatmentLymphoma, B-Cell2
2Active Not RecruitingTreatmentLymphoma, Extranodal NK-T-Cell / T-Cell Lymphomas1
2Active Not RecruitingTreatmentLymphoma, Hodgkins3
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
2Active Not RecruitingTreatmentLymphoproliferative Disorders1
2Active Not RecruitingTreatmentMalignant Lymphomas13
2Active Not RecruitingTreatmentMalignant Lymphomas / Nonneoplastic Condition1
2Active Not RecruitingTreatmentMalignant Neoplasm of Esophagus1
2Active Not RecruitingTreatmentMalignant Neoplasm of Female Breast1
2Active Not RecruitingTreatmentMetastatic Melanoma1
2Active Not RecruitingTreatmentMetastatic Melanoma / Skin Cancers1
2Active Not RecruitingTreatmentMetastatic Ocular Melanoma / Metastatic Uveal Melanoma1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)8
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2Active Not RecruitingTreatmentMultiple Myeloma in Relapse / Multiple Myeloma, Refractory1
2Active Not RecruitingTreatmentMyalgic Encephalomyelitis (ME)1
2Active Not RecruitingTreatmentNeoadjuvant Operable Breast Cancer1
2Active Not RecruitingTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
2Active Not RecruitingTreatmentNeoplasms, Breast1
2Active Not RecruitingTreatmentNephritis, Lupus1
2Active Not RecruitingTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentNeuroblastomas / Sarcomas1
2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentPreviously Treated Metastatic Adenocarcinoma of the Pancreas1
2Active Not RecruitingTreatmentPrimary Mediastinal Large B Cell Lymphoma1
2Active Not RecruitingTreatmentRecurrent Nasopharyngeal Undifferentiated Carcinoma / Stage IV Nasopharyngeal Undifferentiated Carcinoma1
2Active Not RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
2Active Not RecruitingTreatmentSarcomas1
2Active Not RecruitingTreatmentSickle Cell Disorders2
2Active Not RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Active Not RecruitingTreatmentStage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma / Stages III Skin Melanoma1
2Active Not RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
2CompletedNot AvailableCancer, Breast1
2CompletedDiagnosticMalignant Lymphomas1
2CompletedDiagnosticNeoplasms1
2CompletedPreventionGrade 3/4 Neutropenia / Neutropenia, Febrile1
2CompletedPreventionHodgkins Disease (HD) / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedScreeningLeukemias / Malignant Lymphomas / Smith-Magenis Syndrome1
2CompletedSupportive CareBrain and Central Nervous System Tumors1
2CompletedSupportive CareCancer, Breast / Cancer, Ovarian / Drug/Agent Toxicity by Tissue/Organ / Lung Cancers / Malignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions / Secondary Myelofibrosis / Small Intestine Cancer1
2CompletedSupportive CareDiarrhea / Gastrointestinal Complications / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedSupportive CareDrug/Agent Toxicity by Tissue/Organ / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Oral Complications / Radiation Toxicity1
2CompletedSupportive CareGraft Versus Host Disease (GVHD)1
2CompletedSupportive CareLeukemias / Malignant Lymphomas / Oral Complications1
2CompletedSupportive CareNeuroendocrine Tumors1
2CompletedTreatment2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer1
2CompletedTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Promyelocytic Leukemia (M3) / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Myeloid Leukemia in Remission / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Philadelphia Chromosome Negative Chronic Myelogenous Leukemia / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Multiple Myeloma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hematopoietic/Lymphoid Cancer / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)4
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Myelodysplastic Syndrome1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2CompletedTreatmentAcute Lymphoblastic Leukemia, Mature B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL)1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Aplastic Anaemia (AA) / Biphenotypic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Hodgkins Disease (HD) / Leukemia Acute Myeloid Leukemia (AML) / Malignant Lymphomas / Myelodysplastic Syndromes / Plasma Cell Neoplasms1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Chronic Myeloid Leukemia (CML) / Histiocytosis / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplasia1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Splenic Marginal Zone Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAdult Acute Lymphoblastic Leukemia in Remission1
2CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Pleomorphic Rhabdomyosarcoma / Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Rhabdomyosarcoma1
2CompletedTreatmentAll / Aplastic Anaemia (AA) / CLL / CML Chronic Phase, Accelerated Phase, or Blast Crisis / Leukemia Acute Myeloid Leukemia (AML) / Multiple Myeloma (MM) / MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) / RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA / Smith-Magenis Syndrome1
2CompletedTreatmentAlveolar Childhood Rhabdomyosarcoma / Embryonal Childhood Rhabdomyosarcoma / Embryonal-botryoid Childhood Rhabdomyosarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma1
2CompletedTreatmentAmyloidosis1
2CompletedTreatmentAnal Carcinoma / Cervical Cancers / Oropharyngeal Cancers / Penile Cancer / Vaginal Cancers1
2CompletedTreatmentAnaplastic Large Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAnemia, Hemolytic, Autoimmune / Autoimmune Diseases / Felty's Syndrome / Thrombocytopenic Purpura1
2CompletedTreatmentAnti-p53 TCR-Gene1
2CompletedTreatmentAplastic Anaemia (AA)2
2CompletedTreatmentB-All / Burkitt's Lymphoma1
2CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia1
2CompletedTreatmentB-Chronic Lymphocytic Leukemia1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentB-cell Chronic Lymphocytic Leukemia CLL1
2CompletedTreatmentBehcet's Syndrome1
2CompletedTreatmentBeta-Thalassemia / Hematologic Diseases / Hematopoietic Stem Cell Transplantation (HSCT) / Sickle Cell Disorders1
2CompletedTreatmentBlood Cancers / Multiple Myeloma (MM)1
2CompletedTreatmentBlood Stem Cell Transplant Failure / Leukemias / Malignancies, Hematologic1
2CompletedTreatmentBlood and Marrow Transplant (BMT) / Multiple Myeloma (MM) / Transplantation, Autologous / Transplantation, Homologous1
2CompletedTreatmentBrain and Central Nervous System Tumors7
2CompletedTreatmentBrain and Central Nervous System Tumors / Head and Neck Carcinoma / Malignant Lymphomas1
2CompletedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas1
2CompletedTreatmentBreast Cancer Invasive Nos1
2CompletedTreatmentBurkitt's Lymphoma / Burkitt'S-like Lymphoma1
2CompletedTreatmentCancer, Breast48
2CompletedTreatmentCancer, Breast / Cancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentCancer, Breast / Cardiac Toxicity1
2CompletedTreatmentCancer, Breast / Cognitive/Functional Effects / Depression / Malnutrition / Psychosocial Effects of Cancer and Its Treatment1
2CompletedTreatmentCancer, Breast / Colorectal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas / Mesothelioma, Malignant / Renal Cancers1
2CompletedTreatmentCancer, Breast / Drug/Agent Toxicity by Tissue/Organ1
2CompletedTreatmentCancer, Breast / Elderly1
2CompletedTreatmentCancer, Breast / Fevers / Neutropenias1
2CompletedTreatmentCancer, Breast / HER2-Negative Breast Cancer1
2CompletedTreatmentCancer, Breast / Invasive Breast Carcinoma / Metastatic Breast Carcinoma1
2CompletedTreatmentCancer, Breast / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentCancer, Breast / Neoplasms, Breast3
2CompletedTreatmentCancer, Breast / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentCancer, Breast / Stage I Breast Carcinoma / Stage II Breast Cancer1
2CompletedTreatmentCancer, Ovarian2
2CompletedTreatmentCancer, Ovarian / Extragonadal Germ Cell Tumor1
2CompletedTreatmentCancer, Ovarian / Extragonadal Germ Cell Tumor / Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Ovarian / Sarcomas / Small Intestine Cancer1
2CompletedTreatmentCancers1
2CompletedTreatmentCancers / Leukemias / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentCarcinoma of Unknown Primary / Lung Cancers1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric / Leukemias / Malignant Lymphomas / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentChildhood Renal Cell Carcinoma / Clear Cell Renal Cell Carcinoma / Clear Cell Sarcoma of the Kidney / Papillary Renal Cell Carcinoma / Rhabdoid Tumors of the Kidney (RTK) / Stage I Renal Cell Cancer / Stage I Renal Wilms Tumor / Stage II Renal Cell Cancer / Stage II Renal Wilms Tumor / Stage III Renal Cell Cancer / Stage III Renal Wilms Tumor / Stage IV Renal Cell Cancer / Stage IV Renal Wilms Tumor1
2CompletedTreatmentChronic Leukemias / Chronic Lymphocytic Leukaemia (CLL) / Leukemia, B-Cell / Leukemias1
2CompletedTreatmentChronic Lung Diseases / Pulmonary Fibrosis / Sarcoidosis1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)6
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias4
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentChronic Myelogenous Leukemia (CML)1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition / Small Intestine Cancer1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Small Intestine Cancer1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Multiple Myeloma and Malignant Plasma Cell Neoplasms / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms2
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentChronic Myeloproliferative Disorders / Secondary Myelofibrosis1
2CompletedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2CompletedTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2CompletedTreatmentDiffuse Large Cell Lymphoma1
2CompletedTreatmentDisseminated Sclerosis1
2CompletedTreatmentEngraftment Syndrome / Graft Versus Host Disease (GVHD) / Renal Cell Adenocarcinoma1
2CompletedTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Triple-Negative Breast Carcinoma1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Her2-Positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2CompletedTreatmentEstrogen Receptor-Positive Breast Cancer / Her2-Positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentEwing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Peripheral Primitive Neuroectodermal Tumor / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2CompletedTreatmentEwing's Sarcoma (ES) / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas1
2CompletedTreatmentFemale Breast Cancer1
2CompletedTreatmentFollicular Lymphoma (FL)2
2CompletedTreatmentGerm Cell Tumors / Testicular Neoplasms1
2CompletedTreatmentGlomerulonephritis minimal lesion / Systemic Lupus Erythematosus (SLE)1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Secondary Myelofibrosis1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Thymic Carcinoma1
2CompletedTreatmentGranulomatosis With Polyangiitis / Microscopic Polyangiitis / Renal Limited Vasculitis1
2CompletedTreatmentGranulomatosis With Polyangiitis / Vasculitis1
2CompletedTreatmentHER2 Negative Breast Cancer1
2CompletedTreatmentHead and Neck Carcinoma / Head and Neck Squamous Cell Carcinoma (HNSCC)1
2CompletedTreatmentHematologic Diseases / Leukemias / Malignant Lymphomas / Plasma Cell Myeloma1
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Hodgkin Disease / Lymphoma, Hodgkins / Malignant Lymphomas2
2CompletedTreatmentHodgkins Disease (HD) / Pediatric1
2CompletedTreatmentHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphoma, AIDS Related1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentIndividualized Chemotherapy1
2CompletedTreatmentInflammatory carcinoma of the breast / Locally Advanced Breast Cancer (LABC)1
2CompletedTreatmentInflammatory carcinoma of the breast / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2CompletedTreatmentInterstitial Lung Disease (ILD) / Scleroderma1
2CompletedTreatmentJuvenile Myelomonocytic Leukemia1
2CompletedTreatmentKidney Failure,Chronic / Transplantation, Kidney1
2CompletedTreatmentLeukemia, Lymphocytic, Acute / Leukemia, Myelocytic, Acute / Leukemia,Myeloid, Chronic / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLeukemia, Lymphocytic, Chronic1
2CompletedTreatmentLeukemia, Prolymphocytic / Leukemias1
2CompletedTreatmentLeukemias31
2CompletedTreatmentLeukemias / Malignant Lymphomas17
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes4
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Myeloproliferative Disorders / Renal Cancers1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myleoma / Myelodysplastic Syndrome / Myeloproliferative Disorders1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes2
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic-Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases2
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms2
2CompletedTreatmentLeukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes4
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases3
2CompletedTreatmentLeukemias / Neutropenias / Thrombocytopenias1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2CompletedTreatmentLung Cancers2
2CompletedTreatmentLupus Erythematosus, Systemic1
2CompletedTreatmentLupus Erythematosus, Systemic / Nephritis, Lupus1
2CompletedTreatmentLymphocytic Leukemia, Chronic4
2CompletedTreatmentLymphoma, B-Cell1
2CompletedTreatmentLymphoma, Hodgkins1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / POOR PROGNOSIS1
2CompletedTreatmentMale Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer1
2CompletedTreatmentMalignancies, Hematologic2
2CompletedTreatmentMalignant Lymphomas66
2CompletedTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm2
2CompletedTreatmentMalignant Lymphomas / Neurotoxicity1
2CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer1
2CompletedTreatmentMalignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentMalignant Melanoma / Melanoma / Melanoma, Experimental1
2CompletedTreatmentMalignant Neoplasm of Pancreas3
2CompletedTreatmentMannosidosis / Mucolipidosis Type II (I-cell Disease) / Mucopolysaccharidosis VI / Type 1 Mucopolysaccharidosis1
2CompletedTreatmentMantle Cell Lymphoma (MCL)3
2CompletedTreatmentMelanoma2
2CompletedTreatmentMelanoma (Skin)4
2CompletedTreatmentMelanoma (Skin) / Renal Cancers1
2CompletedTreatmentMelanoma / Neoplasms Metastasis1
2CompletedTreatmentMelanoma / Skin Cancers2
2CompletedTreatmentMetastatic Beast Cancer1
2CompletedTreatmentMetastatic Kidney Cancer / Metastatic Melanoma1
2CompletedTreatmentMetastatic Melanoma1
2CompletedTreatmentMetastatic Melanoma / Skin Cancers1
2CompletedTreatmentMultiple Myeloma (MM)11
2CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm11
2CompletedTreatmentNeoplasms, Brain / Neuroblastomas / Tumors, Central Nervous System1
2CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System2
2CompletedTreatmentNeoplasms, Breast8
2CompletedTreatmentNeoplasms, Malignant1
2CompletedTreatmentNeoplasms, Ovarian1
2CompletedTreatmentNephritis, Lupus / Systemic Lupus Erythematosus (SLE)1
2CompletedTreatmentNeuroblastomas11
2CompletedTreatmentNeuroendocrine Carcinoma of the Skin1
2CompletedTreatmentNeutropenias / Sarcomas1
2CompletedTreatmentNon-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)3
2CompletedTreatmentPathological Response Rate1
2CompletedTreatmentPemphigus1
2CompletedTreatmentPlasma Cell Myeloma1
2CompletedTreatmentPrimary Peritoneal Carcinoma / Recurrent Ovarian Carcinoma / Stage IV Ovarian Cancer1
2CompletedTreatmentPrimary Systemic Amyloidosis2
2CompletedTreatmentProstate Cancer2
2CompletedTreatmentRectal Carcinoma1
2CompletedTreatmentRelapsed Follicular Lymphoma1
2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
2CompletedTreatmentRenal Cancers2
2CompletedTreatmentRenal Cancers / Sarcomas1
2CompletedTreatmentRetinoblastoma2
2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentSarcoma, Osteogenic1
2CompletedTreatmentSarcomas5
2CompletedTreatmentSclerosis, Progressive Systemic1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2CompletedTreatmentT-cell-prolymphocytic Leukemia1
2CompletedTreatmentTo Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients1
2CompletedTreatmentTriple Negative Breast Cancer (TNBC)1
2CompletedTreatmentTumors, Solid1
2CompletedTreatmentUnilateral HER2 Positive Breast Cancer1
2CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentUntreated Childhood Medulloblastoma1
2CompletedTreatmentUntreated T-Cell Angioimmunoblastic Lymphoma1
2Enrolling by InvitationTreatmentAcute,Leukemia, Lymphoid1
2Not Yet RecruitingTreatmentAnemias / ASXL1 Gene Mutation / EZH2 Gene Mutation / IDH1 Gene Mutation / IDH2 Gene Mutation / Plasma Cell Myeloma / Primary Myelofibrosis / Recurrent Plasma Cell Myeloma / Secondary Myelofibrosis / Thrombocytopenias1
2Not Yet RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Leukemia in Remission / Acute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukemia With FLT3/ITD Mutation / Acute Myeloid Leukemia With Gene Mutations / Agnogenic Myeloid Metaplasia / Aplastic Anaemia (AA) / B-cell Non-Hodgkin's Lymphomas / CD40 Ligand Deficiency / Chronic Granulomatous Disease (CGD) / Chronic Leukemia in Remission / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Congenital Amegakaryocytic Thrombocytopenia / Congenital neutropenia / Congenital Pure Red Cell Aplasia / Glanzmann Thrombasthenia / Immunodeficiency Syndrome / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Plasma Cell Myeloma / Polycythemia Vera (PV) / Recurrent Non-Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Severe Aplastic Anemia (SAA) / Shwachman-Diamond Syndrome / Sickle Cell Disorders / T-Cell Non-Hodgkin Lymphoma / Thalassaemic disorders / Waldenstrom's Macroglobulinemia (WM) / Wiskott-Aldrich Syndrome (WAS)1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Burkitt Leukemia/Lymphoma / Hematopoietic/Lymphoid Cancer / Lymphoma, Lymphoblastic1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Childhood Cancers / Down Syndrome (DS)1
2Not Yet RecruitingTreatmentAggressive Non-Hodgkin Lymphoma1
2Not Yet RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent B Lymphoblastic Lymphoma / Recurrent T Lymphoblastic Leukemia/Lymphoma / Refractory B Lymphoblastic Lymphoma / Refractory T Lymphoblastic Lymphoma / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma1
2Not Yet RecruitingTreatmentCancer, Advanced / Cancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Carcinoma1
2Not Yet RecruitingTreatmentCancer, Breast1
2Not Yet RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2Not Yet RecruitingTreatmentIdiopathic Refractory Scleritis1
2Not Yet RecruitingTreatmentLeukemia, Acute / Smith-Magenis Syndrome1
2Not Yet RecruitingTreatmentLocally Advanced Breast Cancer (LABC)1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Breast1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Female Genital Organs1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Pancreas2
2Not Yet RecruitingTreatmentMetastatic Colorectal Cancers1
2Not Yet RecruitingTreatmentMetastatic Melanoma1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)3
2Not Yet RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
2Not Yet RecruitingTreatmentStage II Breast Cancer / Stage III Breast Cancer1
2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2Not Yet RecruitingTreatmentUntreated Childhood Medulloblastoma1
2RecruitingBasic ScienceCancer, Breast1
2RecruitingPreventionAcute Leukemia in Remission / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Primary Myelofibrosis1
2RecruitingPreventionAcute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingPreventionAcute myeloid leukaemia (in remission) / Adult Acute Lymphoblastic Leukemia in Complete Remission / Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission / Chronic Myelomonocytic Leukemia in Remission / Graft Versus Host Disease (GVHD) / Lymphoma, Hodgkins / Minimal Residual Disease / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma / Severe Aplastic Anemia (SAA) / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingPreventionAgnogenic Myeloid Metaplasia / Allogeneic Transplant / Leukemias / Malignant Lymphomas / Myelodysplastic Syndrome / Severe Aplastic Anemia (SAA)1
2RecruitingPreventionChronic Myeloid Leukemia (CML) / Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Myelodysplastic Syndromes1
2RecruitingPreventionGraft Versus Host Disease (GVHD)1
2RecruitingPreventionMultiple Myeloma (MM)1
2RecruitingSupportive CareChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Follicular Lymphoma (FL) / Graft Versus Host Disease (GVHD) / Leukaemia, Acute / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Secondary Myelodysplastic Syndromes1
2RecruitingSupportive CareGliomas1
2RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Stage III AIDS-related Lymphoma / Stage IV AIDS-related Lymphoma1
2RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Leukemias of Ambiguous Lineage / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Graft Versus Host Disease (GVHD) / Lymphoma, Lymphoblastic / Myelodysplastic Syndrome With Excess Blasts / Myelodysplastic Syndrome With Excess Blasts-1 / Myelodysplastic Syndrome With Excess Blasts-2 / RAEB-1 / RAEB-2 / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Acute Lymphoblastic Leukemia / Refractory Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts1
2RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Erythroid Leukemia in Remission / Acute Leukemia in Remission / Acute Megakaryoblastic Leukemia / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Acute Myeloid Leukemia With FLT3/ITD Mutation / Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 / Acute Myeloid Leukemia With Inv(3)(q21q26.2); RPN1-EVI1 / Acute Myeloid Leukemia With Multilineage Dysplasia / Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214 / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Complete Remission / B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) / B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Complete Remission / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Myelodysplastic Syndrome / Recurrent Anaplastic Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Secondary Acute Myeloid Leukemia / T Lymphoblastic Lymphoma1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma / Acute Myelogenous Leukaemia (AML) / Acute Undifferentiated Leukemia (AUL) / Chemotherapy-sensitive Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute erythroid leukemia / Acute Lymphoblastic Leukemia in Remission / Acute Megakaryoblastic Leukemia / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Blasts Under 10 Percent of Bone Marrow Nucleated Cells / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Pancytopenia / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Secondary Acute Myeloid Leukemia1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Complete Remission / Adult Acute Myeloid Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Aggressive Non-Hodgkin Lymphoma / Agnogenic Myeloid Metaplasia / B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Complete Remission / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Leukemia, Prolymphocytic / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome With Excess Blasts / Pancytopenia / Plasma Cell Myeloma / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia With Excess Blasts1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Hematopoietic Cell Transplantation Recipient / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Prolymphocytic / Loss of Chromosome 17p / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Hodgkin Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Recurrent Waldenstrom Macroglobulinemia / T-cell chronic lymphocytic leukaemia1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myelogenous Leukemia (CML) / Familial Hemophagocytic Lymphohistiocytosis (FLH) / Hemophagocytic Lymphohistiocytosis (HLH) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Non Hodgkins Lymphoma / Viral-associated Hemophagocytic Syndrome (VAHS) / X-linked Lymphoproliferative Disease (XLP)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myeloid Leukemia (CML) / Granulocytic Sarcoma / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2RecruitingTreatmentAcute Lymphoblastic Leukemia/Lymphoma / Biphenotypic/Undifferentiated/Prolymphocytic Leukemias / Bone Marrow Failure Syndromes / Burkitt's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukaemia, Acute / Leukemia Acute Myeloid Leukemia (AML) / Leukemia or MDS in Aplasia / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Lymphoma, Hodgkins / Lymphoma, Large-Cell / Lymphoma, Mantle-Cell / Lymphoplasmacytic Lymphoma / Marginal Zone B-Cell Lymphoma / MRD Positive Leukemia / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms/Myelofibrosis / Myeloproliferative Syndromes / Natural Killer Cell Malignancies / Recurrent Cutaneous T-cell lymphoma / Relapsed Chronic Lymphocytic Leukemia / Relapsed Multiple Myeloma / Relapsed Small Lymphocytic Lymphoma / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / CMML / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Burkitt's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Hematological Diseases / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Lymphoma, B-Cell / Lymphoma, Lymphoblastic / Lymphoma, Mantle-Cell / Lymphoplasmacytic Lymphoma / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myeloproliferative Syndromes / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Prolymphocytic / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Refractory Anemia / Smith-Magenis Syndrome1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Syndromes / Non-Hodgkin's Lymphoma (NHL) / Other Diseases of Blood and Blood-Forming Organs1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Congenital Hypoplastic Anemia / Myelodysplastic Syndromes (MDS) / Severe Marrow Failure1
2RecruitingTreatmentAcute myeloid leukaemia (in remission) / Aplastic Anaemia (AA) / Chronic Myelomonocytic Leukemia / Indolent Non-Hodgkin's Lymphomas / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Neoplasms, Malignant / Plasma Cell Myeloma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts1
2RecruitingTreatmentAdenocarcinomas / Advanced NSCLC / Carcinoma, Adenosquamous / Metastatic Non-Small Cell Lung Cancer / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Aplastic Anaemia (AA) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia / Refractory Anemia With Ringed Sideroblasts / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Urticaria Pigmentosa / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Lymphoblastic Lymphoma / CD20 Positive / Philadelphia Chromosome Positive1
2RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia1
2RecruitingTreatmentAdult T-Cell Leukemia/Lymphoma / Anaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Angioimmunoblastic T-Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage III Anaplastic Large Cell Lymphoma / Stage IV Anaplastic Large Cell Lymphoma1
2RecruitingTreatmentAdult-onset Immunodeficiency1
2RecruitingTreatmentAgnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Chronic Myeloproliferative Disorders / Essential Thrombocythemia (ET) / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myelodysplastic Syndromes / Plasma Cell Dyscrasia / Plasma Cell Neoplasms / Polycythemia Vera (PV) / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2RecruitingTreatmentAntineoplastic Combined Chemotherapy Protocols1
2RecruitingTreatmentAplastic Anaemia (AA) / Bone Marrow Failure / Immunosuppression / Severe Aplastic Anemia (SAA)1
2RecruitingTreatmentAplastic Anaemia (AA) / Immunodeficiency Syndrome / Non-Cancer Diagnosis / Severe Aplastic Anemia (SAA)1
2RecruitingTreatmentAtypical Teratoid Rhabdoid Tumors (ATRT) / Malignant Rhabdoid Tumors (MRT)1
2RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Hypodiploidy / Leukemia, Plasma Cell / Loss of Chromosome 17p / Progression of Multiple Myeloma or Plasma Cell Leukemia / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Non-Hodgkin's lymphoma / Refractory Plasma Cell Myeloma / Refractory Small Lymphocytic Lymphoma / T(14;16) / T(4;14) / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentB-cell Acute Lymphoblastic Leukemia1
2RecruitingTreatmentBRCA1 Hereditary Breast and Ovarian Cancer Syndrome1
2RecruitingTreatmentBeta Thalassemia / Bone Marrow Failure / Histiocytosis / Immunodeficiencies / Inborn Errors of Metabolism / Leukemias / Malignant Lymphomas / Sickle Cell Disorders1
2RecruitingTreatmentBilateral Breast Carcinoma / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Stage IB Breast Cancer / Stage IB Breast Cancer AJCC v7 / Stage II Breast Cancer / Stage II Breast Cancer AJCC v6 and v7 / Stage IIA Breast Cancer / Stage IIA Breast Cancer AJCC v6 and v7 / Stage IIB Breast Cancer / Stage IIB Breast Cancer AJCC v6 and v7 / Stage III Breast Cancer / Stage III Breast Cancer AJCC V7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v7 / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v7 / Stage IIIC Breast Cancer / Stage IIIC Breast Cancer AJCC v7 / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v7 / Triple-Negative Breast Carcinoma / Unilateral Breast Carcinoma1
2RecruitingTreatmentBone Marrow Failure Syndromes / Severe Aplastic Anemia (SAA)1
2RecruitingTreatmentBreast Adenocarcinoma / Breast Cancer Metastatic / Breast Cancer Stage II / Breast Cancer Stage III / Estrogen Receptor- Negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2/Neu Negative / Invasive Adenocarcinoma of the Breast / Invasive Breast Carcinoma / Locally Advanced Breast Cancer (LABC) / Progesterone Receptor Negative / Progesterone Receptor Positive Tumor / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentCancer, Breast12
2RecruitingTreatmentCancer, Breast / Cervical Cancers / Malignant Melanoma / Melanoma / Metastatic Cancer That Express the MAGE-A3-DP4 Antigen / Oesophageal Carcinoma / Renal Cancers / Sarcomas / Urothelial Cancer1
2RecruitingTreatmentCancer, Breast / Hepatocellular Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Metastatic Cancers Other Than Melanoma That Express ESO Antigen / Synovial Sarcoma1
2RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentCancer, Ovarian1
2RecruitingTreatmentCancers1
2RecruitingTreatmentCervical Cancers / Endometrial Cancers / Uterine Cancers1
2RecruitingTreatmentCervical Squamous Cell Carcinoma In Situ / Vulvar High Grade Squamous Intraepithelial Lesion1
2RecruitingTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Embryonal Tumor With Abundant Neuropil and True Rosettes / Metastatic Malignant Neoplasm to the Leptomeninges / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma1
2RecruitingTreatmentChondrosarcoma, Mesenchymal / Conventional Chondrosarcoma / Dedifferentiated Chondrosarcoma / Myxoid Liposarcoma1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias2
2RecruitingTreatmentColorectal Cancer Stage IV / Metastatic Colorectal Cancers / TP53 Gene Mutation1
2RecruitingTreatmentColorectal Cancers1
2RecruitingTreatmentCongenital Hypoplastic Anemia1
2RecruitingTreatmentDOCK8 Deficiency1
2RecruitingTreatmentEarly Primary Breast Cancer in the Elderly1
2RecruitingTreatmentEarly Stage Breast Cancer1
2RecruitingTreatmentEpidermolysis Bullosa2
2RecruitingTreatmentEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma1
2RecruitingTreatmentEsophageal Cancers1
2RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / Estrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Her2-Positive Breast Cancer / HER2/Neu Negative / HER2/Neu Positive / Invasive Breast Carcinoma / Progesterone Receptor Negative / Progesterone Receptor Positive / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC) / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentEwing's Sarcoma (ES)1
2RecruitingTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Serous Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
2RecruitingTreatmentFibrolamellar Hepatocellular Carcinoma / Hepatocellular Carcinoma (Fibrolamellar Variant) / Hepatocellular,Carcinoma1
2RecruitingTreatmentGATA2 / Immunodeficiencies / Smith-Magenis Syndrome1
2RecruitingTreatmentGlioblastomas / Gliosarcoma1
2RecruitingTreatmentGrade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Follicular Lymphoma / Refractory Follicular Lymphoma1
2RecruitingTreatmentGraft Survival / HLA-mismatched Bone Marrow Transplantation / Myeloablative Conditioning / Transplantion, Bone Marrow1
2RecruitingTreatmentHER2 Positive Breast Cancers / Inflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
2RecruitingTreatmentHER2 Positive Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer1
2RecruitingTreatmentHHV-8 / Human Immunodeficiency Virus (HIV) / Lymphoproliferative Disorders / Malignancies1
2RecruitingTreatmentHaematological Malignancies1
2RecruitingTreatmentHematopoietic Malignancies1
2RecruitingTreatmentHematopoietic and Lymphoid Cell Neoplasm1
2RecruitingTreatmentHematopoietic/Lymphoid Cancer1
2RecruitingTreatmentHenoch-Schoenlein Purpura Nephritis1
2RecruitingTreatmentHer2-Positive Breast Cancer1
2RecruitingTreatmentHer2-Positive Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2RecruitingTreatmentHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast / Inflammatory carcinoma of the breast1
2RecruitingTreatmentInflammatory carcinoma of the breast1
2RecruitingTreatmentIntracranial Germinoma1
2RecruitingTreatmentIntracranial Non-germinomatous Germ Cell Tumor1
2RecruitingTreatmentLarge Granular Lymphocytes Leukemia1
2RecruitingTreatmentLeukaemia, Lymphoblastic1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)2
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias / Myeloid Leukemias1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2RecruitingTreatmentLeukemia, Lymphoblastic, Acute / Leukemias / Lymphoma, Lymphoblastic1
2RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
2RecruitingTreatmentLeukemias7
2RecruitingTreatmentLeukemias / Malignant Lymphomas1
2RecruitingTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
2RecruitingTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myeloproliferative Disorders1
2RecruitingTreatmentLeukemias / Malignant Lymphomas / Myeloproliferative Disorders / Plasma Cell Myeloma1
2RecruitingTreatmentLeukemias / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentLocally Advanced Breast Cancer (LABC) / Metastatic Breast Carcinoma1
2RecruitingTreatmentLymphoma, Hodgkins2
2RecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)4
2RecruitingTreatmentLymphoma, Mantle-Cell / Malignant Lymphomas1
2RecruitingTreatmentMalignancies, Hematologic1
2RecruitingTreatmentMalignant Lymphomas3
2RecruitingTreatmentMalignant Neoplasm of Breast1
2RecruitingTreatmentMalignant Neoplasm of Pancreas2
2RecruitingTreatmentMedulloblastomas2
2RecruitingTreatmentMedulloblastomas / Neuroblastomas1
2RecruitingTreatmentMelanoma4
2RecruitingTreatmentMetastatic Breast Cancer (MBC)2
2RecruitingTreatmentMetastatic Cholangiocarcinoma / Metastatic Colorectal Cancers / Metastatic Gastric Cancers / Metastatic Hepatocellular Carcinoma / Pancreatic Cancer Metastatic1
2RecruitingTreatmentMetastatic Melanoma1
2RecruitingTreatmentMetastatic Thyroid Cancer1
2RecruitingTreatmentMetastatic, Stage III or Stage IV, Melanoma1
2RecruitingTreatmentMulticentric Castleman Disease1
2RecruitingTreatmentMultiple Myeloma (MM)9
2RecruitingTreatmentMyelodysplastic Syndromes1
2RecruitingTreatmentNeoplasms, Breast2
2RecruitingTreatmentNeoplasms, Hematologic1
2RecruitingTreatmentNeoplasms, Malignant1
2RecruitingTreatmentNephritis, Lupus1
2RecruitingTreatmentNeuroblastoma Recurrent1
2RecruitingTreatmentNeuroblastomas2
2RecruitingTreatmentNeutropenias1
2RecruitingTreatmentNewly Diagnosed Ewing Sarcoma1
2RecruitingTreatmentNewly Diagnosed High Risk Neuroblastoma1
2RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2RecruitingTreatmentPlasma Cell Myeloma1
2RecruitingTreatmentPosttransplant Lymphoproliferative Disorder1
2RecruitingTreatmentPrimary Myelofibrosis / Secondary Myelofibrosis1
2RecruitingTreatmentRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma2
2RecruitingTreatmentRecurrent Primary Amyloidosis1
2RecruitingTreatmentRefractory and/or Relapsed Metastatic Solid Tumors1
2RecruitingTreatmentRelapse/Refractory Multiple Myeloma1
2RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
2RecruitingTreatmentRelapsed/Refractory Malignant Lymphomas1
2RecruitingTreatmentResidual Tumor / Triple-Negative Invasive Breast Carcinoma1
2RecruitingTreatmentRetinoblastoma2
2RecruitingTreatmentRhabdomyosarcomas1
2RecruitingTreatmentSarcoma, Osteogenic1
2RecruitingTreatmentSarcomas1
2RecruitingTreatmentScleroderma, Systemic1
2RecruitingTreatmentSevere Aplastic Anemia (SAA)2
2RecruitingTreatmentSickle Cell Disorders2
2RecruitingTreatmentSquamous Cell Carcinoma of the Oral Cavity2
2RecruitingTreatmentStage I Mantle Cell Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2RecruitingTreatmentStage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentTumors, Solid1
2RecruitingTreatmentUnresectable Localized Soft Tissue Sarcoma1
2SuspendedTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Indolent Non-Hodgkin's Lymphomas / Leukemia Acute Myeloid Leukemia (AML) / Malignant Lymphoma, Large Cell Type / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Chronic Lymphocytic Leukemia / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Follicular Lymphoma / Refractory Hodgkin Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Refractory Small Lymphocytic Lymphoma / T-Cell Non-Hodgkin Lymphoma1
2SuspendedTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma1
2SuspendedTreatmentCrohn's Disease (CD)1
2SuspendedTreatmentProstatic Neoplasms1
2TerminatedDiagnosticCancer, Breast1
2TerminatedDiagnosticMalignant Lymphomas1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelocytic Leukemia / Chronic Myelocytic Leukemia / Granulocytic Sarcoma / Hodgkin's or Non-Hodgkin's Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / All / Chronic Lymphocytic Leukaemia (CLL) / CLL / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Lymphoma, Hodgkins / Malignancies, Hematologic / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myelogenous Leukemia (CML) / Granulocytic Sarcoma / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentAcute Myelogenous Leukaemia (AML) / Refractory Acute Myelogenous Leukemia1
2TerminatedTreatmentAllogeneic Transplantation / Chronic Granulomatous Disease (CGD) / Combined Immune Deficiency / Congenital Hypoplastic Anemia / Genetic Diseases / Metabolic Diseases / Pediatrics / Peripheral Blood Stem Cell Transplantation / Thalassaemic disorders / Transplantation, Bone Marrow / Transplantation, Stem Cell / Wiskott-Aldrich Syndrome (WAS) / X-Linked Lymphoproliferative Disease1
2TerminatedTreatmentAlpha Mannosidosis / Aspartylglucosaminuria / Fucosidosis / Hurler's Syndrome / Krabbe's Disease / Mucopolysaccharidosis VI / Niemann-Pick Disease Type B / Niemann-Pick Disease, Type C / Sly Syndrome / Sphingolipidoses / Wolman's Disease1
2TerminatedTreatmentAnaplastic Large Cell Lymphoma1
2TerminatedTreatmentAplastic Anaemia (AA)1
2TerminatedTreatmentAplastic Anaemia (AA) / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM)1
2TerminatedTreatmentAtypical Burkitt Lymphoma / Burkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentBone Cancer / Ewing's Sarcoma (ES)1
2TerminatedTreatmentBrain and Central Nervous System Tumors / Drug/Agent Toxicity by Tissue/Organ / Malignant Lymphomas / Thrombocytopenias1
2TerminatedTreatmentBreast Cancer, Metastatic / Cancer treatment1
2TerminatedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
2TerminatedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast / Tumors, Breast1
2TerminatedTreatmentCancer, Breast8
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentCancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Fallopian Tubes / Ovarian / Primary Peritoneal / Primary Peritoneal Cancer / Serous Carcinoma / Serous Carcinoma Cancer / Triple-Negative Breast / Triple-Negative Breast Cancer (TNBC)1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Hodgkins Disease (HD) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphoblastic, Acute / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, B-Cell / Malignant Lymphomas / Non Hodgkin Lymphoma (NHL)1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases1
2TerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2TerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2TerminatedTreatmentDisseminated Sclerosis1
2TerminatedTreatmentEarly-Stage Breast Cancer1
2TerminatedTreatmentEwing's Sarcoma (ES)1
2TerminatedTreatmentHaematological Malignancies1
2TerminatedTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders / Thalassaemic disorders1
2TerminatedTreatmentHematologic Diseases1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentIntraocular Melanoma / Malignant Conjunctival Neoplasm1
2TerminatedTreatmentLeukemia, Lymphocytic, Chronic / Small Lymphocytic Lymphoma (SLL)1
2TerminatedTreatmentLeukemia, Myelogenous, Acute1
2TerminatedTreatmentLeukemia, Prolymphocytic / Leukemias1
2TerminatedTreatmentLeukemias5
2TerminatedTreatmentLeukemias / Lymphoma, Lymphoblastic / Malignant Lymphomas / Precursor-B Acute Lymphoblastic Leukemia1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndrome1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Other Haematological Diseases1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
2TerminatedTreatmentLeukemias / Pediatric Cancer1
2TerminatedTreatmentLocally Advanced HER2-negative Breast Cancer1
2TerminatedTreatmentLymphatic Diseases / Lymphoma, B-Cell1
2TerminatedTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentLymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2TerminatedTreatmentLymphoma, Lymphoblastic1
2TerminatedTreatmentMalignancies, Hematologic1
2TerminatedTreatmentMalignant Lymphomas4
2TerminatedTreatmentMalignant Melanoma Stage IV1
2TerminatedTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Primary Peritoneal Carcinoma / Stage III Ovarian Cancer / Undifferentiated Ovarian Carcinoma1
2TerminatedTreatmentMedulloblastomas / Neoplasms, Brain / Primitive Neuroectodermal Tumor / Tumors, Central Nervous System1
2TerminatedTreatmentMelanoma (Skin)2
2TerminatedTreatmentMelanoma (Skin) / Renal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
2TerminatedTreatmentMelanoma / Skin Cancers1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)2
2TerminatedTreatmentMetastatic Cancers / Metastatic Melanoma1
2TerminatedTreatmentMetastatic Cancers / Metastatic Melanoma / Metastatic Renal Cell Cancer1
2TerminatedTreatmentMetastatic Cutaneous Melanoma1
2TerminatedTreatmentMetastatic Melanoma1
2TerminatedTreatmentMetastatic Melanoma / Skin Cancers4
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2TerminatedTreatmentNeoplasms, Breast1
2TerminatedTreatmentNeuroblastomas2
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)2
2TerminatedTreatmentPemphigus Vulgaris (PV)1
2TerminatedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2TerminatedTreatmentRefractory Multiple Myeloma1
2TerminatedTreatmentRelapsed Acute Myelogenous Leukemia1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2TerminatedTreatmentSarcomas1
2TerminatedTreatmentSickle Cell Disorders1
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2Unknown StatusSupportive CareChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2Unknown StatusTreatmentAcquired Aplastic Anemia1
2Unknown StatusTreatmentAnaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL)1
2Unknown StatusTreatmentAplastic Anaemia (AA)2
2Unknown StatusTreatmentB-Cell Chronic Lymphocytic Leukemia / B-cell Non-Hodgkin's Lymphomas / Immunocytoma/Morbus Waldenström1
2Unknown StatusTreatmentB-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Small Lymphocytic Lymphoma / Hematopoietic/Lymphoid Cancer / Noncontiguous Stage II Small Lymphocytic Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma1
2Unknown StatusTreatmentBortezomib / Cyclophosphamide / Dexamethasone / Granulocyte Colony-Stimulating Factor / Plasma Cell Myeloma1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors2
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Neuroblastomas1
2Unknown StatusTreatmentBreast Diseases / Cancer, Breast / Neoplasms / Neoplasms by Site1
2Unknown StatusTreatmentCancer, Breast17
2Unknown StatusTreatmentCancer, Breast / Stage II Breast Cancer / Stage III Breast Cancer1
2Unknown StatusTreatmentChildhood Langerhans Cell Histiocytosis / Congenital Hypoplastic Anemia / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL) / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia1
2Unknown StatusTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Malignant Plasma Cell Neoplasms / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Secondary Myelofibrosis1
2Unknown StatusTreatmentChurg-Strauss Syndrome (CSS) / Granulomatosis With Polyangiitis / Microscopic Polyangiitis / Polyarteritis Nodosa1
2Unknown StatusTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Precancerous Conditions1
2Unknown StatusTreatmentHER2-Negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Unknown StatusTreatmentHIV-associated Hodgkin Lymphoma1
2Unknown StatusTreatmentHematopoietic/Lymphoid Cancer1
2Unknown StatusTreatmentLeukemias3
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
2Unknown StatusTreatmentLiver Cancer1
2Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
2Unknown StatusTreatmentLymphoid Blastic Phase of Chronic Myeloid Leukemia / Philadelphia Positive Acute Lymphoblastic Leukemia1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentLymphoma, Mantle-Cell1
2Unknown StatusTreatmentMalignant Lymphomas12
2Unknown StatusTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
2Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
2Unknown StatusTreatmentMultiple Myeloma (MM)1
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2Unknown StatusTreatmentNHL With Hemophagocytic Lymphohistiocytosis1
2Unknown StatusTreatmentNephritis, Lupus1
2Unknown StatusTreatmentNeuroblastomas1
2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentPain / Prostate Cancer1
2Unknown StatusTreatmentProsthesis Survival1
2Unknown StatusTreatmentRenal Cancers3
2Unknown StatusTreatmentSarcomas2
2Unknown StatusTreatmentStage I Breast Carcinoma / Stage II Breast Cancer1
2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2WithdrawnSupportive CareMalignancies, Hematologic1
2WithdrawnTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2WithdrawnTreatmentActive Chronic Graft Versus Host Disease1
2WithdrawnTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML)1
2WithdrawnTreatmentAcute Myelogenous Leukaemia (AML)1
2WithdrawnTreatmentAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Retinoblastoma / Sarcomas1
2WithdrawnTreatmentCancer, Breast4
2WithdrawnTreatmentChronic Inflammatory Demyelinating Polyneuropathy (CIDP)1
2WithdrawnTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2WithdrawnTreatmentCrohn's Disease (CD)1
2WithdrawnTreatmentDisseminated Sclerosis1
2WithdrawnTreatmentLeukemias2
2WithdrawnTreatmentMalignant Lymphomas6
2WithdrawnTreatmentMetastatic Melanoma1
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentNeoplasms, Breast1
2WithdrawnTreatmentScleroderma, Systemic1
2WithdrawnTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2, 3Active Not RecruitingTreatmentAplastic Anaemia (AA) / Dyskeratosis Congenita1
2, 3Active Not RecruitingTreatmentCancer, Breast1
2, 3Active Not RecruitingTreatmentChediak-Higashi Syndrome / Griscelli Syndrome / Hematologic Diseases / Histiocytosis, Langerhans-Cell / Immunologic Diseases / Lymphohistiocytosis, Hemophagocytic / X-Linked Lymphoproliferative Disorders1
2, 3Active Not RecruitingTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma1
2, 3Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2, 3Active Not RecruitingTreatmentCongenital Hypoplastic Anemia / Severe Congenital Neutropenia / Shwachman-Diamond Syndrome / Sickle Cell Disorders / Thalassaemic disorders1
2, 3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2, 3CompletedTreatmentANCA Associated Systemic Vasculitis / Granulomatosis With Polyangiitis / Microscopic Polyangiitis1
2, 3CompletedTreatmentAdrenoleukodystrophy / Fucosidosis / Gangliosidosis, GM1 / Gaucher's Disease / Juvenile Neuronal Ceroid Lipofuscinosis / Leukodystrophy, Globoid Cell / Metachromatic Leukodystrophy / Sandhoff Disease / Sphingomyelin Lipidosis / Tay Sachs Disease / Wolman's Disease1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2, 3CompletedTreatmentAutoimmune Diseases / Scleroderma, Systemic / Sclerosis1
2, 3CompletedTreatmentCancer, Breast1
2, 3CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2, 3CompletedTreatmentGranulomatosis With Polyangiitis / Microscopic Polyangiitis / Vasculitis1
2, 3CompletedTreatmentImmune Thrombocytopenic Purpura ( ITP )1
2, 3CompletedTreatmentLeukaemia, Acute1
2, 3CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
2, 3CompletedTreatmentLymphoma, Large-Cell, Diffuse1
2, 3CompletedTreatmentVasculitis1
2, 3Not Yet RecruitingSupportive CareChemotherapy Induced Neutropenia1
2, 3Not Yet RecruitingTreatmentStage III Breast Cancer1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma1
2, 3RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Allogeneic peripheral haematopoietic stem cell transplant / Busulfan / Total Body Irradiation1
2, 3RecruitingTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Conditioning / Myelodysplastic Syndrome1
2, 3RecruitingTreatmentAutologous Hematopoietic Stem Cell Transplantation / Conditioning / Leukemia Acute Myeloid Leukemia (AML)1
2, 3RecruitingTreatmentAutologous Hematopoietic Stem Cell Transplantation / Conditioning / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2, 3RecruitingTreatmentCancer, Breast1
2, 3RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2, 3RecruitingTreatmentChildhood Ependymoma1
2, 3RecruitingTreatmentCongenital Hypoplastic Anemia1
2, 3RecruitingTreatmentIdiopathic Inflammatory Myositis / Interstitial Lung Disease (ILD) / Mixed Connective Tissue Disease (MCTD) / Scleroderma1
2, 3RecruitingTreatmentLeukemias2
2, 3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2, 3RecruitingTreatmentMature B-Cell Lymphoma1
2, 3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
2, 3RecruitingTreatmentNeoplasms, Brain1
2, 3TerminatedTreatmentCancer, Breast1
2, 3TerminatedTreatmentFollicular Lymphoma (FL) / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma1
2, 3TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphocytic, Acute / Smith-Magenis Syndrome1
2, 3TerminatedTreatmentMalignant Lymphomas1
2, 3TerminatedTreatmentOral Cavity Cancer1
2, 3Unknown StatusPreventionLeukemias / Multiple Myeloma (MM)1
2, 3Unknown StatusTreatmentBone Marrow Failure / Congenital Hypoplastic Anemia / Osteopetrosis / Severe Combined Immunodeficiency1
2, 3Unknown StatusTreatmentCancer, Breast1
2, 3Unknown StatusTreatmentMucopolysaccharidosis1
2, 3Unknown StatusTreatmentNephritis, Lupus1
2, 3Unknown StatusTreatmentOsteopetrosis1
2, 3Unknown StatusTreatmentSevere Osteopetrosis1
3Active Not RecruitingNot AvailableBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Children / Ototoxicity1
3Active Not RecruitingNot AvailableCancer, Breast1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAdult Malignant Mesenchymoma / Adult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Botryoid-Type Embryonal Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Childhood Malignant Mesenchymoma / Non-Metastatic Childhood Soft Tissue Sarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
3Active Not RecruitingTreatmentAdult Renal Wilms Tumor / Beckwith-Wiedemann Syndrome / Childhood Renal Wilms Tumor / Diffuse Hyperplastic Perilobar Nephroblastomatosis / Hemihypertrophy / Stage I Renal Wilms Tumor / Stage II Renal Wilms Tumor / Stage III Renal Wilms Tumor / Stage IV Renal Wilms Tumor / Stage V Renal Wilms Tumor1
3Active Not RecruitingTreatmentAdult Rhabdomyosarcoma / Embryonal Childhood Rhabdomyosarcoma / Embryonal-botryoid Childhood Rhabdomyosarcoma / Previously Untreated Childhood Rhabdomyosarcoma1
3Active Not RecruitingTreatmentAdult Supratentorial Primitive Neuroectodermal Tumor (PNET) / Childhood Supratentorial Primitive Neuroectodermal Tumor / Ewing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Peripheral Primitive Neuroectodermal Tumor of the Kidney / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3Active Not RecruitingTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL) / T-Cell Lymphomas1
3Active Not RecruitingTreatmentAnemias / Chronic Lymphocytic Leukaemia (CLL) / Fever, Sweats, and Hot Flashes / Hepatomegaly / Lymphadenopathy / Lymphocytosis / Small Lymphocytic Lymphoma (SLL) / Splenomegaly / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma / Thrombocytopenias / Tiredness / Weight Changes1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Graft Versus Host Disease (GVHD) / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Non Hodgkin's Lymphoma / Mature B-cell Leukemia Burkitt-type1
3Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
3Active Not RecruitingTreatmentBreast Adenocarcinoma / HER2 Positive Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer1
3Active Not RecruitingTreatmentBreast Cancer Invasive Nos1
3Active Not RecruitingTreatmentCancer, Breast17
3Active Not RecruitingTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentChildhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentChoroid Plexus Tumors1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
3Active Not RecruitingTreatmentDiffuse Large B Cell Lymphoma CD20 Positive / Diffuse Large B Cell Lymphoma CD20+1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Male Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
3Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Positive / Progesterone Receptor Negative / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIC Breast Cancer1
3Active Not RecruitingTreatmentExtraocular Retinoblastoma1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL)1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoplasmacytic Lymphoma / Marginal Zone Lymphoma / Small Lymphocytic Lymphoma (SLL)1
3Active Not RecruitingTreatmentHER2/Neu Positive / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
3Active Not RecruitingTreatmentHer2 Non-overexpressing / Primary Breast Cancer1
3Active Not RecruitingTreatmentLarge B Cell Lymphoma1
3Active Not RecruitingTreatmentLeukemia, Lymphocytic, Chronic1
3Active Not RecruitingTreatmentLeukemias2
3Active Not RecruitingTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3Active Not RecruitingTreatmentLymphoblastic Leukemia, Acute1
3Active Not RecruitingTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentLymphoma, Hodgkins1
3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentLymphoma, Mantle-Cell1
3Active Not RecruitingTreatmentMalignant Lymphomas8
3Active Not RecruitingTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)4
3Active Not RecruitingTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
3Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentRetinal Neoplasms / Retinoblastoma1
3Active Not RecruitingTreatmentSarcomas1
3Active Not RecruitingTreatmentStage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q / Stage IV Wilms Tumor1
3Active Not RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
3CompletedPreventionCancer, Breast1
3CompletedPreventionChronic Lung Diseases / Pulmonary Fibrosis / Scleroderma, Systemic1
3CompletedSupportive CareCancer, Breast1
3CompletedSupportive CareCancer, Breast / Chemotherapy Induced Neutropenia1
3CompletedSupportive CareCancer, Breast / Infertilities / Menopausal Symptoms2
3CompletedSupportive CareCancers1
3CompletedSupportive CareCancers / Leukemias / Malignant Lymphomas1
3CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Myelodysplastic Syndrome / Natural Killer Cell Lymphoblastic Leukemia/Lymphoma1
3CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute Myeloid Leukemia/Transient Myeloproliferative Disorder / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
3CompletedTreatmentAdult Malignant Mesenchymoma / Adult Rhabdomyosarcoma / Alveolar Childhood Rhabdomyosarcoma / Childhood Malignant Mesenchymoma / Embryonal Childhood Rhabdomyosarcoma / Embryonal-botryoid Childhood Rhabdomyosarcoma / Nonmetastatic Childhood Soft Tissue Sarcoma / Previously Untreated Childhood Rhabdomyosarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma1
3CompletedTreatmentAdvanced HCC1
3CompletedTreatmentAplastic Anaemia (AA)1
3CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia1
3CompletedTreatmentBrain and Central Nervous System Tumors1
3CompletedTreatmentCancer, Breast58
3CompletedTreatmentCancer, Breast / Chemotherapy, Adjuvant1
3CompletedTreatmentCancer, Breast / Cyclophosphamide / Doxorubicin / High Risk / Positive Nodes1
3CompletedTreatmentCancer, Ovarian2
3CompletedTreatmentCardiac Toxicity / Malignant Lymphomas1
3CompletedTreatmentChildhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentChildhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
3CompletedTreatmentChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma / Childhood Mixed Cellularity Classical Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Classical Hodgkin Lymphoma / Malignant Lymphomas / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3CompletedTreatmentChildhood Malignant Fibrous Histiocytoma of Bone / Sarcomas1
3CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
3CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
3CompletedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
3CompletedTreatmentEarly Stage Breast Cancer1
3CompletedTreatmentEarly-Stage Breast Cancer1
3CompletedTreatmentElderly Patients (>65 Years) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentGlomerulonephritis, Membranous1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignant Lymphomas1
3CompletedTreatmentHER2 Positive Breast Cancers / Inflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentIdiopathic Nephrotic Syndrome1
3CompletedTreatmentInflammatory carcinoma of the breast1
3CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)3
3CompletedTreatmentLeukemia, Myelocytic, Acute1
3CompletedTreatmentLeukemias18
3CompletedTreatmentLeukemias / Malignant Lymphomas4
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
3CompletedTreatmentLung Cancers2
3CompletedTreatmentLymphocytic Leukemia, Chronic1
3CompletedTreatmentLymphoma, Diffuse Large-Cell1
3CompletedTreatmentLymphoma, Hodgkins2
3CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
3CompletedTreatmentMalignant Lymphomas15
3CompletedTreatmentMalignant Neoplasm of Female Breast1
3CompletedTreatmentMetastatic Renal Cell Carcinoma1
3CompletedTreatmentMultiple Myeloma (MM)5
3CompletedTreatmentMultiple Myeloma de Novo Treatment1
3CompletedTreatmentMultiple Sclerosis, Chronic Progressive1
3CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
3CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System / Untreated Childhood Medulloblastoma1
3CompletedTreatmentNeoplasms, Breast4
3CompletedTreatmentNephritis, Lupus1
3CompletedTreatmentNephritis, Lupus / Systemic Lupus Erythematosus (SLE)1
3CompletedTreatmentNeuroblastomas8
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
3CompletedTreatmentRecurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma1
3CompletedTreatmentRenal Cancers2
3CompletedTreatmentSarcomas2
3CompletedTreatmentScleroderma1
3CompletedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3CompletedTreatmentStage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Small Lymphocytic Lymphoma1
3CompletedTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor2
3CompletedTreatmentVenereal Warts1
3Not Yet RecruitingPreventionAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
3Not Yet RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / NMYC Gene Amplification / Recurrent Neuroblastoma1
3Not Yet RecruitingTreatmentGestational Trophoblastic Neoplasms1
3Not Yet RecruitingTreatmentHER2 Positive Breast Cancers1
3Not Yet RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3Not Yet RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)1
3Not Yet RecruitingTreatmentSevere Forms of Mucous Membrane Pemphigoid1
3RecruitingPreventionLeukaemia, Acute / Myelodysplasia1
3RecruitingTreatmentANCA-Associated Vasculitis (AAV)1
3RecruitingTreatmentAcquired Haemophilia1
3RecruitingTreatmentActivated B-Cell-Like Diffuse Large B-Cell Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Diffuse Large B-Cell Lymphoma Activated B-Cell Type / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / High Grade B-Cell Lymphoma, Not Otherwise Specified / Recurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / BCR/ABL1 Fusion Protein Negative / Untreated Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentAdult B Lymphoblastic Lymphoma / Childhood B Acute Lymphoblastic Leukemia / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Lymphoblastic Lymphoma / Down Syndrome (DS) / Stage I B Lymphoblastic Lymphoma / Stage II B Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAmyloidosis1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Carcinoma1
3RecruitingTreatmentBreast Cancer Metastatic / Breast Cancer Stage IIIA / Breast Cancer, Stage IIIB1
3RecruitingTreatmentBreastcancer / Neutropenias1
3RecruitingTreatmentCancer, Breast2
3RecruitingTreatmentChildhood Hodgkin Lymphoma / Classical Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
3RecruitingTreatmentChildhood Infratentorial Ependymoma / Childhood Supratentorial Ependymoma / Newly Diagnosed Childhood Ependymoma1
3RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
3RecruitingTreatmentClassical Hodgkin Lymphoma2
3RecruitingTreatmentEosinophilic Granulomatosis With Polyangiitis (EGPA)1
3RecruitingTreatmentEwing's Sarcoma (ES)1
3RecruitingTreatmentFollicular Lymphoma (FL)1
3RecruitingTreatmentFollicular Non-Hodgkin's Lymphoma1
3RecruitingTreatmentGanglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma1
3RecruitingTreatmentGlomerulonephritis membranous1
3RecruitingTreatmentGlomerulonephritis minimal lesion1
3RecruitingTreatmentGlomerulonephritis, Membranous1
3RecruitingTreatmentHematopoietic Stem Cell Transplantation (HSCT)1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentInflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Mucinous Breast Cancer / Tubular Breast Carcinoma1
3RecruitingTreatmentInterstitial Lung Disease (ILD) / Pulmonary Fibrosis / Scleroderma / Sclerosis, Progressive Systemic1
3RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)5
3RecruitingTreatmentMalignant Lymphomas1
3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
3RecruitingTreatmentMetastatic Ewing Sarcoma / Metastatic Malignant Neoplasm in the Bone / Metastatic Malignant Neoplasm in the Bone Marrow / Metastatic Malignant Neoplasm in the Lung / Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone / Peripheral Primitive Neuroectodermal Tumor of Soft Tissues1
3RecruitingTreatmentMetastatic Melanoma1
3RecruitingTreatmentMultiple Myeloma (MM)4
3RecruitingTreatmentNephritis, Lupus1
3RecruitingTreatmentNeuroblastomas1
3RecruitingTreatmentNeuroblastomas / Opsoclonus Myoclonus Syndrome1
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentRelapse Multiple Myeloma1
3RecruitingTreatmentRelapsed or Refractory Systemic Light Chain Amyloidosis1
3RecruitingTreatmentThrombocytopenias1
3RecruitingTreatmentTriple Negative Breast Neoplasms1
3RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
3RecruitingTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3SuspendedTreatmentBotryoid-Type Embryonal Rhabdomyosarcoma / Rhabdomyosarcoma, Alveolar / Rhabdomyosarcoma, Embryonal / Rhabdomyosarcomas / Sclerosing Rhabdomyosarcoma / Spindle Cell Rhabdomyosarcoma / Untreated Childhood Rhabdomyosarcoma1
3SuspendedTreatmentBrain Cancer / Choroid Plexus Tumors1
3SuspendedTreatmentCancer, Breast1
3SuspendedTreatmentMalignant Lymphomas1
3TerminatedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
3TerminatedHealth Services ResearchFollicular Lymphoma (FL)1
3TerminatedPreventionAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Myeloproliferative Disorders1
3TerminatedTreatmentANCA Associated Systemic Vasculitis Including Wegener’s / Granulomatosis and Microscopic Polyangiitis and / Renal Limited Vasculitis1
3TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentAnti-r-HuEpo Associated PRCA Subjects1
3TerminatedTreatmentCancer, Breast6
3TerminatedTreatmentCancer, Ovarian1
3TerminatedTreatmentCardiac Toxicity / Inflammatory carcinoma of the breast / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IV Breast Cancer1
3TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
3TerminatedTreatmentLeukemia, Myelocytic, Acute1
3TerminatedTreatmentLeukemias1
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3TerminatedTreatmentLymphoma, Extranodal NK-T-Cell1
3TerminatedTreatmentMalignant Lymphomas3
3TerminatedTreatmentMultiple Myeloma (MM)1
3TerminatedTreatmentNephritis, Lupus3
3Unknown StatusDiagnosticCancer, Breast1
3Unknown StatusSupportive CareUnspecified Adult Solid Tumor, Protocol Specific1
3Unknown StatusTreatmentAplastic Anaemia (AA)1
3Unknown StatusTreatmentBrain and Central Nervous System Tumors1
3Unknown StatusTreatmentCancer, Breast11
3Unknown StatusTreatmentCancer, Breast / Cardiac Toxicity / Perioperative/Postoperative Complications1
3Unknown StatusTreatmentCancer, Ovarian1
3Unknown StatusTreatmentCarcinoma of Unknown Primary1
3Unknown StatusTreatmentExtragonadal Germ Cell Tumor / Testicular germ cell tumour1
3Unknown StatusTreatmentFollicular Lymphoma (FL)1
3Unknown StatusTreatmentGranulomatosis With Polyangiitis / Vasculitis1
3Unknown StatusTreatmentIPI≥2 / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Unknown StatusTreatmentLeukemias7
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
3Unknown StatusTreatmentLeukemias / Mucositis / Oral Complications1
3Unknown StatusTreatmentLeukemias / Neutropenias1
3Unknown StatusTreatmentLung Cancers3
3Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
3Unknown StatusTreatmentLymphoma, Mantle-Cell1
3Unknown StatusTreatmentMalignant Lymphomas14
3Unknown StatusTreatmentMultiple Myeloma (MM)1
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm5
3Unknown StatusTreatmentNeuroblastomas5
3Unknown StatusTreatmentNonneoplastic Condition1
3Unknown StatusTreatmentRenal Cancers1
3Unknown StatusTreatmentSarcomas2
3WithdrawnTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas1
3WithdrawnTreatmentLeukemias1
3WithdrawnTreatmentSarcomas1
4Active Not RecruitingTreatmentCancer, Breast1
4Active Not RecruitingTreatmentMultiple Myeloma (MM)1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)5
4CompletedTreatmentAdult Acute Lymphocytic Leukemia4
4CompletedTreatmentAnemias / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentCancer, Breast1
4CompletedTreatmentLocally Advanced Breast Cancer (LABC)1
4CompletedTreatmentLymphocytic Leukemia, Chronic2
4CompletedTreatmentLymphoma, Lymphoblastic1
4CompletedTreatmentNephritis, Lupus1
4CompletedTreatmentNon Burkitt / Post-transplant Lymphoproliferative Disease (PTLD)1
4CompletedTreatmentUveitis1
4Not Yet RecruitingTreatmentAplastic Anaemia (AA)1
4Not Yet RecruitingTreatmentChronic Leukemias / Juvenile Myelomonocytic Leukemia / Leukaemia, Acute / Myelodysplastic Syndrome1
4RecruitingNot AvailableBMI >30 kg/m2 / Cancer, Breast1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
4RecruitingTreatmentCancer, Breast4
4RecruitingTreatmentGlycogen Storage Disease Type II (GSD-II) / Glycogenesis 2 Acid Maltase Deficiency / Pompe's Disease1
4RecruitingTreatmentImpaired Renal Function / Infection NOS1
4RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
4RecruitingTreatmentMalignant Lymphomas1
4RecruitingTreatmentMantle Cell Lymphoma (MCL)1
4RecruitingTreatmentNeoplasms, Breast1
4RecruitingTreatmentThalassemia Major (TM)1
4Unknown StatusNot AvailableRhabdomyosarcomas1
4Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL) / Non-Hodgkin's Lymphoma (NHL)1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia2
4Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL)1
4Unknown StatusTreatmentChurg-Strauss Syndrome (CSS)1
4Unknown StatusTreatmentMicroscopic Polyangiitis / Polyarteritis Nodosa1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast / Chemotherapeutic Agent Toxicity / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Adults / Neurotoxicity / Psychosocial Effects of Cancer and Its Treatment / Tiredness1
Not AvailableActive Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Plasma Cell Neoplasms / Primary Systemic Amyloidosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Neuroblastoma / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Regional Neuroblastoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableActive Not RecruitingTreatmentBurkitt's Lymphoma / Chronic Myelogenous Leukemia (CML) / Leukaemia, Acute1
Not AvailableActive Not RecruitingTreatmentCancer, Breast1
Not AvailableActive Not RecruitingTreatmentCancer, Breast / Pregnancy1
Not AvailableActive Not RecruitingTreatmentChildhood Lymphocyte Predominant Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
Not AvailableActive Not RecruitingTreatmentLeukemias2
Not AvailableActive Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
Not AvailableActive Not RecruitingTreatmentLeukemias / Myelodysplastic Syndromes1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas2
Not AvailableActive Not RecruitingTreatmentMalignant Neoplasm of Pancreas2
Not AvailableActive Not RecruitingTreatmentMedulloblastomas / Pinealoblastoma / Supratentorial Embryonal Tumor, Not Otherwise Specified / Untreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
Not AvailableActive Not RecruitingTreatmentMetastatic Melanoma2
Not AvailableCompletedNot AvailableAdverse Effects / Lupus Erythematosus, Systemic1
Not AvailableCompletedNot AvailableCancer, Breast1
Not AvailableCompletedNot AvailableCancer, Breast / Metastatic Cancers1
Not AvailableCompletedNot AvailableEarly Diffuse Cutaneous Systemic Sclerosis1
Not AvailableCompletedNot AvailableLymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma1
Not AvailableCompletedSupportive CareCancer, Breast / Cancer, Ovarian / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Nausea and Vomiting / Neuroblastomas / Testicular germ cell tumour1
Not AvailableCompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableCompletedSupportive CareMale Breast Cancer / Nausea and Vomiting / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer1
Not AvailableCompletedSupportive CareMultiple Myeloma (MM)1
Not AvailableCompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T-Cell Leukemia/Lymphoma / Burkitt's Lymphoma / Lymphoid Malignancies (New or Relapsed) / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL)1
Not AvailableCompletedTreatmentAdenocarcinoma of the Breast / Cancer, Breast1
Not AvailableCompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Myelodysplastic Syndrome With Isolated Del(5q) / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
Not AvailableCompletedTreatmentAntiphospholipid Antibody Syndrome / Systemic Lupus Erythematosus (SLE)1
Not AvailableCompletedTreatmentAplastic Anaemia (AA)2
Not AvailableCompletedTreatmentAtaxia-Telangiectasia1
Not AvailableCompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors1
Not AvailableCompletedTreatmentCancer, Breast7
Not AvailableCompletedTreatmentCancer, Breast / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer1
Not AvailableCompletedTreatmentCancer, Ovarian / Sarcomas1
Not AvailableCompletedTreatmentChildhood Germ Cell Tumor / Extragonadal Germ Cell Tumor1
Not AvailableCompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableCompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
Not AvailableCompletedTreatmentCongenital Hypoplastic Anemia2
Not AvailableCompletedTreatmentCongenital Hypoplastic Anemia / Leukemia, Lymphocytic, Acute / Leukemia, Nonlymphocytic, Acute / Myelodysplastic Syndromes1
Not AvailableCompletedTreatmentDisseminated Neuroblastoma / Ganglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableCompletedTreatmentEwing Sarcoma of Bone / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
Not AvailableCompletedTreatmentHenoch-Schoenlein Purpura (HSP)1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentL1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Non-T, Non-B Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
Not AvailableCompletedTreatmentLeukemias1
Not AvailableCompletedTreatmentLeukemias / Malignant Lymphomas1
Not AvailableCompletedTreatmentLymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentLymphoma, Lymphoblastic1
Not AvailableCompletedTreatmentMalignant Lymphomas4
Not AvailableCompletedTreatmentNephritis, Lupus1
Not AvailableCompletedTreatmentNeutropenias / Red-Cell Aplasia, Pure / Sickle Cell Disorders / Thalassemia Major (TM)1
Not AvailableCompletedTreatmentRenal Cancers1
Not AvailableCompletedTreatmentT-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableNot Yet RecruitingTreatmentAdenocarcinoma of Esophagogastric Junction / B Cell Leukemias / Carcinoma, Pancreatic / Hepatocellular,Carcinoma / Lymphoma, B Cell / Plasma Cell Myeloma1
Not AvailableNot Yet RecruitingTreatmentDisseminated Sclerosis1
Not AvailableNot Yet RecruitingTreatmentHLA-A2 Positive Cells Present / Metastatic Malignant Neoplasm / Metastatic Malignant Neoplasm in the Brain1
Not AvailableNot Yet RecruitingTreatmentTumor Gastric / Tumor, Colorectal1
Not AvailableRecruitingNot AvailableCancer, Breast1
Not AvailableRecruitingNot AvailableIgA Nephropathy / Immunosuppressive Treatment / Proteinuria in Nephrotic Range1
Not AvailableRecruitingNot AvailableLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes / Precursor Cell Lymphoblastic Leukemia-Lymphoma1
Not AvailableRecruitingNot AvailablePrimary Graft Failure / Secondary Graft Failure1
Not AvailableRecruitingHealth Services ResearchCancer, Breast1
Not AvailableRecruitingOtherSevere Aplastic Anemia (SAA)1
Not AvailableRecruitingTreatmentAIDS Related Non-Hodgkin Lymphoma / AIDS-Related Burkitt Lymphoma / AIDS-Related Diffuse Large B-cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Myelogenous Leukemia (CML) / Lymphoid Malignancies / Lymphoma, Hodgkins / Myelodysplastic Syndromes / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Relapsed Chronic Lymphocytic Leukemia / Relapsed Non-Hodgkin's Lymphoma1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
Not AvailableRecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Agnogenic Myeloid Metaplasia / Burkitt's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Lymphoblastic / Lymphoma, Mantle-Cell / Lymphoplasmacytic Lymphoma / Marginal Zone B-Cell Lymphoma / Multiple Myeloma (MM) / Myelodysplasia / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL)1
Not AvailableRecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
Not AvailableRecruitingTreatmentAplastic Anaemia (AA) / Dyskeratosis Congenita1
Not AvailableRecruitingTreatmentBare Lymphocyte Syndrome / CD40 Ligand Deficiency / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Griscelli Syndrome / Hyper IgM Syndrome / Langerhan's Cell Histiocytosis / Lymphohistiocytosis, Hemophagocytic / Omenn's Syndrome / Reticular Dysgenesis / SCID / Wiskott-Aldrich Syndrome (WAS) / X-Linked Lymphoproliferative Disease1
Not AvailableRecruitingTreatmentBreast Cancer Nos Premenopausal1
Not AvailableRecruitingTreatmentClassical Hodgkins Lymphoma in Children and Adolescents1
Not AvailableRecruitingTreatmentCongenital Pediatric Disorders1
Not AvailableRecruitingTreatmentGraft Versus Host Disease (GVHD) / Hematopoietic/Lymphoid Cancer1
Not AvailableRecruitingTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders1
Not AvailableRecruitingTreatmentHodgkins Disease (HD) / JMML / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphocytic, Acute / Leukemia, Lymphocytic, Chronic / Leukemia,Myeloid, Chronic / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Smith-Magenis Syndrome1
Not AvailableRecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
Not AvailableRecruitingTreatmentMalignancies, Hematologic1
Not AvailableRecruitingTreatmentMalignant Lymphomas1
Not AvailableRecruitingTreatmentMedulloblastomas1
Not AvailableRecruitingTreatmentMultiple Myeloma (MM)1
Not AvailableRecruitingTreatmentMyeloid Hematological Malignancies1
Not AvailableRecruitingTreatmentNeoplasms Metastasis / Neoplasms, Breast1
Not AvailableRecruitingTreatmentNeuroblastomas2
Not AvailableRecruitingTreatmentPleuropulmonary Blastoma1
Not AvailableRecruitingTreatmentROHHAD Syndrome1
Not AvailableRecruitingTreatmentStage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
Not AvailableSuspendedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableTerminatedNot AvailableCancer, Breast1
Not AvailableTerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Lymphoma, Mantle-Cell / Multiple Myeloma (MM) / Myelodysplasia / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis1
Not AvailableTerminatedTreatmentBruton's agammaglobulinemia / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Immunologic Deficiency Syndromes / Leukocyte Adhesion Deficiency Syndrome / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Virus-Associated Hemophagocytic Syndrome / Wiskott-Aldrich Syndrome (WAS) / X-Linked Hyper IgM Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableTerminatedTreatmentCancers / Leukemias / Lymphoma, Hodgkins / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Congenital Hypoplastic Anemia / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Sarcomas1
Not AvailableTerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
Not AvailableTerminatedTreatmentEpidermolysis Bullosa1
Not AvailableTerminatedTreatmentFSGS1
Not AvailableTerminatedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
Not AvailableTerminatedTreatmentHemoglobin SC / Sickle Cell Disorders1
Not AvailableTerminatedTreatmentLeukemias / Lymphoma, Hodgkins / Myeloproliferative Disorders / Non Hodgkin Lymphoma (NHL)1
Not AvailableTerminatedTreatmentLeukemias / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentMalignant Lymphomas1
Not AvailableTerminatedTreatmentSickle Cell Disorders / Sickle Cell-hemoglobin C Disease / Sickle Cell-β0-thalassemia1
Not AvailableTerminatedTreatmentThalassaemic disorders1
Not AvailableUnknown StatusNot AvailableCancer, Breast1
Not AvailableUnknown StatusNot AvailableChronic Lymphocytic Leukaemia (CLL)1
Not AvailableUnknown StatusNot AvailableIdiopathic Membranous Nephropathy1
Not AvailableUnknown StatusNot AvailableUnspecified Childhood Solid Tumor, Protocol Specific1
Not AvailableUnknown StatusSupportive CareGraft Versus Host Disease (GVHD) / Leukemias1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentAnemia, Hemolytic, Autoimmune / Arthritis, Juvenile Rheumatoid / Autoimmune Thrombocytopenic Purpura / Churg-Strauss Syndrome (CSS) / Giant Cells Arteritis / Graft Versus Host Disease (GVHD) / Granu